kool20161231

0001437749-17-002238.txt : 20170213 0001437749-17-002238.hdr.sgml : 20170213 20170213162900 ACCESSION NUMBER: 0001437749-17-002238 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 47 CONFORMED PERIOD OF REPORT: 20161231 FILED AS OF DATE: 20170213 DATE AS OF CHANGE: 20170213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CESCA THERAPEUTICS INC. CENTRAL INDEX KEY: 0000811212 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY APPARATUS & FURNITURE [3821] IRS NUMBER: 943018487 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-82900 FILM NUMBER: 17599576 BUSINESS ADDRESS: STREET 1: 2711 CITRUS ROAD CITY: RANCHO CORDOVA STATE: CA ZIP: 95742 BUSINESS PHONE: 9168585100 MAIL ADDRESS: STREET 1: 2711 CITRUS ROAD CITY: RANCHO CORDOVA STATE: CA ZIP: 95742 FORMER COMPANY: FORMER CONFORMED NAME: THERMOGENESIS CORP DATE OF NAME CHANGE: 19951117 FORMER COMPANY: FORMER CONFORMED NAME: INSTA COOL INC OF NORTH AMERICA DATE OF NAME CHANGE: 19920703 10-Q 1 kool20161231_10q.htm FORM 10-Q kool20161231_10q.htm Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended December 31, 2016.

___

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition from _____________ to _______________.

Commission File Number: 000-16375 Cesca Therapeutics Inc. (Exact name of registrant as specified in its charter)

Delaware (State of incorporation)		94-3018487 (I.R.S. Employer Identification No.)

2711 Citrus Road Rancho Cordova, California 95742 (Address of principal executive offices) (Zip Code)

(916) 858-5100 (Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).

Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [ ] Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Outstanding at February 9, 2017
Common stock, $.001 par value		9.886.402

Table of Contents

Cesca Therapeutics Inc.

INDEX

Page Number

Part I Financial Information

Item 1.	Financial Statements	3

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	24

Item 4.	Controls and Procedures	24

Part II Other Information

Item 1.	Legal Proceedings	25
Item 1A.	Risk Factors	25
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	26
Item 3.	Defaults upon Senior Securities	26
Item 4.	Mine Safety Disclosure	26
Item 5.	Other Information	26
Item 6.	Exhibits	27

Signatures		28

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Cesca Therapeutics Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	December 31, 2016			June 30, 2016
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	4,899		$	5,835
Accounts receivable, net of allowance for doubtful accounts of $57 ($49 at June 30, 2016)		3,019			3,169
Inventories, net of reserves of $1,372 ($1,437 at June 30, 2016)		2,763			3,593
Prepaid expenses and other current assets		260			246
Total current assets		10,941			12,843

Equipment at cost, less accumulated depreciation		3,045			2,962
Goodwill		13,195			13,195
Intangible assets, net		20,614			20,821
Other assets		78			78
Total assets	$	47,873		$	49,899

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	2,059		$	2,648
Accrued payroll and related expenses		1,621			449
Deferred revenue		402			783
Other current liabilities		1,360			1,662
Total current liabilities		5,442			5,542

Noncurrent deferred tax liability		7,641			7,641
Derivative obligations		844			670
Convertible debentures, net		--			2,489
Other noncurrent liabilities		284			1,284
Total liabilities		14,211			17,626

Commitments and contingencies

Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none issued and outstanding		--			--
Common stock, $0.001 par value;150,000,000 shares authorized; 9,886,402 issued and outstanding (3,010,687 at June 30, 2016)		10			3
Paid in capital in excess of par		215,795			188,569
Accumulated deficit		(182,106	)		(156,262	)
Accumulated other comprehensive loss		(37	)		(37	)
Total stockholders’ equity		33,662			32,273

Total liabilities and stockholders’ equity	$	47,873		$	49,899

See accompanying notes.

Page 3

Table of Contents

Cesca Therapeutics Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

(in thousands, except share and per share amounts)

	Three Months Ended December 31,						Six Months Ended December 31,
	2016			2015			2016			2015

Net revenues	$	4,005		$	3,294		$	7,772		$	6,117

Cost of revenues		2,453			2,266			4,838			4,722

Gross profit		1,552			1,028			2,934			1,395


Expenses:

Sales and marketing		294			527			775			1,159

Research and development		694			646			1,364			1,743

General and administrative		4,137			1,823			6,316			4,375

Total operating expenses		5,125			2,996			8,455			7,277

Loss from operations		(3,573	)		(1,968	)		(5,521	)		(5,882	)

Fair value change of derivative instruments		153			2,180			(174	)		3,606
Amortization of debt discount		--			(39	)		(9,851	)		(52	)
Interest expense		(2	)		(14	)		(10,537	)		(21	)
Registration rights liquidated damages		--			(220	)		--			(1,100	)
Loss on cashless exercise of warrants		--			(564	)		--			(564	)
Other income and (expenses)		23			1			239			(8	)
Net loss	$	(3,399	)	$	(624	)	$	(25,844	)	$	(4,021	)

COMPREHENSIVE LOSS
Net loss	$	(3,399	)	$	(624	)	$	(25,844	)	$	(4,021	)
Other comprehensive income:
Foreign currency translation adjustments		(2	)		1			--			(24	)
Comprehensive loss	$	(3,401	)	$	(623	)	$	(25,844	)	$	(4,045	)

Per share data:

Basic and diluted net loss per common share	$	(0.35	)	$	(0.30	)	$	(3.26	)	$	(1.96	)

Weighted average common shares outstanding – basic and diluted		9,849,041			2,069,233			7,932,300			2,048,423

See accompanying notes.

Page 4

Table of Contents

Cesca Therapeutics Inc.

Condensed Consolidated Statements of Cash Flows (Unaudited)

(in thousands)

	Six Months Ended December 31,
	2016			2015
Cash flows from operating activities:
Net loss	$	(25,844	)	$	(4,021	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		473			659
Stock based compensation expense		1,033			304
(Recovery of) reserve for excess and slow-moving inventories		(59	)		311
Amortization of debt discount and issue costs		10,011			62
Change in fair value of derivative		174			(3,606	)
Non-cash accrued interest		10,373			--
Loss on cashless exercise of warrants		--			564
Net change in operating assets and liabilities:
Accounts receivable		149			1,634
Inventories		811			257
Prepaid expenses and other current assets		(13	)		(299	)
Accounts payable		(587	)		(626	)
Accrued payroll and related expenses		1,172			(243	)
Deferred revenue		(381	)		(336	)
Other current liabilities		67			832
Other noncurrent liabilities		51			14

Net cash used in operating activities		(2,570	)		(4,494	)

Net cash used in investing activities:
Capital expenditures		(276	)		(602	)

Cash flows from financing activities:

Proceeds from issuance of common stock, net		2,091			--
Proceeds from convertible debentures, net of financing costs		--			4,720
Payments on capital lease obligations		(46	)		(27	)
Repurchase of common stock		(134	)		(5	)

Net cash provided by financing activities		1,911			4,688

Effects of foreign currency rate changes on cash and cash equivalents		(1	)		(7	)
Net decrease in cash and cash equivalents		(936	)		(415	)

Cash and cash equivalents at beginning of period		5,835			3,357
Cash and cash equivalents at end of period	$	4,899		$	2,942

Supplemental non-cash financing and investing information:
Derivative obligation related to issuance of warrants	$	--		$	4,282
Common stock issued for payment of convertible debentures and interest	$	23,905			--

See accompanying notes.

Page 5

Table of Contents

Cesca Therapeutics Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

(in thousands, except share and per share amounts)

1. Basis of Presentation and Summary of Significant Accounting Policies

Organization and Basis of Presentation

Cesca Therapeutics Inc. (“Cesca”, or the “Company”) develops and markets integrated cellular therapies and delivery systems that advance the safe and effective practice of regenerative medicine. Cesca is a leader in developing and manufacturing automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.

Reverse Stock Split

All historical share amounts disclosed herein have been retroactively recast to reflect the reverse split. No fractional shares were issued; fractional shares of common stock were rounded up to the nearest whole share.

Liquidity and Going Concern

At December 31, 2016, the Company had cash and cash equivalents of $4,899 and working capital of $5,499. The Company has incurred recurring operating losses and as of December 31, 2016 had an accumulated deficit of $182,106. The Company has primarily financed operations through the sale of equity securities, convertible debentures and the sale of certain non-core assets.

The Company will need additional funding to support its phase III Critical Limb Ischemia (“CLIRST III”) trial. As such, management has been exploring additional funding sources, primarily strategic partner relationships. The Company cannot assure that such funding will be available on a timely basis, in needed quantities, or on favorable terms, if at all. If the Company is unable to generate sufficient revenues or obtain additional funds for its working capital needs, the Company will have to further scale-back operations.

Because of recurring and expected operating losses and its cash balance there is substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

Principles of Consolidation

The consolidated financial statements include the accounts of Cesca and its wholly-owned subsidiaries, TotipotentRX Cell Therapy, Pvt. Ltd. and TotipotentSC Scientific Product Pvt. Ltd. All significant intercompany accounts and transactions have been eliminated upon consolidation.

Page 6

Table of Contents

Interim Reporting

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (SEC) rules and regulations and accounting principles applicable for interim periods. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed consolidated financial statements through the date of issuance. Operating results for the six month period ended December 31, 2016, are not necessarily indicative of the results that may be expected for the year ending June 30, 2017. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended June 30, 2016.

2. Summary of Significant Accounting Policies

Revenue Recognition

Revenues from the sale of the Company’s products and services are recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured. The Company generally ships products F.O.B. shipping point. There is no conditional evaluation on any product sold and recognized as revenue. Amounts billed in excess of revenue recognized are recorded as deferred revenue on the balance sheet.

The Company’s sales are generally through distributors. There is no right of return. For sales of products made to distributors, the Company considers a number of factors in determining whether revenue is recognized upon transfer of title to the distributor, or when payment is received. These factors include, but are not limited to, whether the payment terms offered to the distributor are considered to be non-standard, the distributor history of adhering to the terms of its contractual arrangements, the level of inventories maintained by the distributor, whether the Company has a pattern of granting concessions for the benefit of the distributor, and whether there are other conditions that may indicate that the sale to the distributor is not substantive. The Company currently recognizes revenue primarily on the sell-in method with its distributors.

Revenue arrangements with multiple deliverables are divided into units of accounting if certain criteria are met, including whether the deliverable item(s) has (have) value to the customer on a stand-alone basis. Revenue for each unit of accounting is recognized as the unit of accounting is delivered. Arrangement consideration is allocated to each unit of accounting based upon the relative estimated selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables. Estimated selling prices are determined using vendor specific objective evidence of value (VSOE), when available, or an estimate of selling price when VSOE is not available for a given unit of accounting. Significant inputs for the estimates of the selling price of separate units of accounting include market and pricing trends and a customer’s geographic location. The Company accounts for training and installation, service agreements and the collection, processing and testing of the umbilical cord blood and the storage as separate units of accounting.

Service revenue generated from contracts for providing maintenance of equipment is amortized over the life of the agreement. Revenue generated from storage contracts is deferred and recorded ratably over the life of the agreement, up to 21 years. All other service revenue is recognized at the time the service is completed.

Page 7

Table of Contents

Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.

Fair Value Measurements

In accordance with ASC 820, “Fair Value Measurements and Disclosures,” fair value is defined as the exit price, or the amount that would be received for the sale of an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date.

The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.

The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3 within the fair value hierarchy since the valuation model of the derivative obligation is based on unobservable inputs.

Segment Reporting

The Company has one reportable business segment: the research, development and commercialization of autologous cell-based therapies for use in regenerative medicine.

Net Loss per Share

Net loss per share is computed by dividing the net loss to common stockholders by the weighted average number of common shares outstanding. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at December 31:

	2016			2015
Common stock equivalents of convertible debentures		--			404,412
Vested Series A warrants		404,410			404,410
Unvested Series A warrants		698,529	⁽¹⁾		698,529	⁽¹⁾
Vested Series B warrants		--			197,242
Unvested Series B warrants		--			384,191
Warrants – other		3,725,782			252,620
Stock options		321,868			146,838
Restricted stock units		65,148			59,854
Total		5,215,737			2,548,096

⁽¹⁾

Page 8

Table of Contents

Reclassifications

Certain reclassifications have been made from the fiscal 2016 amounts to conform to the fiscal 2017 presentation. These reclassifications did not have any effect on our net loss or stockholders’ equity.

Recently Adopted Accounting Pronouncements

In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-12, “Compensation - Stock Compensation (Topic 718); Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. The amendments in ASU 2014-12 apply to all reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition that affects the vesting of the award. The Company adopted ASU 2014-12 effective July 1, 2016. The Company applies the amendments in ASU 2014-12 prospectively to all awards granted or modified after the effective date. Adoption of the new update to ASU 2014-12 did not have any impact on the financial statements of the Company.

Recently Issued Accounting Pronouncements

In January 2017, the FASB issued ASU 2017-04 which removes Step 2 from the goodwill impairment test. It is effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment test performed with a measurement date after January 1, 2017. The Company has not yet determined the effect that ASU 2017-04 will have on its results of operations, statement of financial position or financial statement disclosures.

In March 2016 the FASB issued ASU No. 2016-06, “Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments” (“ASU 2016-06”). This new standard simplifies the embedded derivative analysis for debt instruments containing contingent call or put options by removing the requirement to assess whether a contingent event is related to interest rates or credit risks. This new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on the Company’s financial position or results of operations.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC Topic 605, “Revenue Recognition” and some cost guidance included in ASC Subtopic 605-35, "Revenue Recognition - Construction-Type and Production-Type Contracts.” The core principle of ASU 2014-09 is that revenue is recognized when the transfer of goods or services to customers occurs in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASU 2014-09 requires the disclosure of sufficient information to enable readers of the Company’s financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. ASU 2014-09 also requires disclosure of information regarding significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 provides two methods of retrospective application. The first method would require the Company to apply ASU 2014-09 to each prior reporting period presented. The second method would require the Company to retrospectively apply ASU 2014-09 with the cumulative effect recognized at the date of initial application. ASU 2014-09 will be effective for the Company beginning in fiscal 2019 as a result of ASU 2015-14, "Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date," which was issued by the FASB in August 2015 and extended the original effective date by one year. The Company is currently evaluating the impact of adopting the available methodologies of ASU 2014-09 and 2015-14 upon its financial statements in future reporting periods. The Company has not yet selected a transition method. The Company is in the process of evaluating the new standard against its existing accounting policies, including the timing of revenue recognition, and its contracts with customers to determine the effect the guidance will have on its financial statements and what changes to systems and controls may be warranted.

Page 9

Table of Contents

There have been four new ASUs issued amending certain aspects of ASU 2014-09, ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross Versus Net)," was issued in March, 2016 to clarify certain aspects of the principal versus agent guidance in ASU 2014-09. In addition, ASU 2016-10, "Identifying Performance Obligations and Licensing," issued in April 2016, amends other sections of ASU 2014-09 including clarifying guidance related to identifying performance obligations and licensing implementation. ASU 2016-12, "Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients" provides amendments and practical expedients to the guidance in ASU 2014-09 in the areas of assessing collectability, presentation of sales taxes received from customers, noncash consideration, contract modification and clarification of using the full retrospective approach to adopt ASU 2014-09. Finally, ASU 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,” was issued in December 2016, and provides elections regarding the disclosures required for remaining performance obligations in certain cases and also makes other technical corrections and improvements to the standard. With its evaluation of the impact of ASU 2014-09, the Company will also consider the impact on its financial statements related to the updated guidance provided by these four new ASUs.

3. Bill Payment Arrangement

The Company entered into a bill payment arrangement whereby Boyalife Group Ltd. (“Payor”), the Company's largest shareholder, will pay the Company’s legal expenses payable to the Company’s attorney related to certain litigation involving SynGen Inc. (the “Bill Payment Arrangement”), although the Company will remain jointly and severally liable for the payment of such legal fees. The terms of the Bill Payment Arrangement provide that the Company will reimburse Payor for any and all amounts paid by Payor in connection with the Bill Payment Arrangement under certain specified events. Any amounts received from Payor will be recorded as a liability until which time such liability has been adjudicated.

4. Commitments and Contingencies

Financial Covenants

Effective September 30, 2015, the Company entered into a Fifth Amended and Restated Technology License and Escrow Agreement with Cord Blood Registry Systems, Inc. which modified the financial covenant that the Company must meet in order to avoid an event of default. The Company must maintain a cash balance and short-term investments net of debt or borrowed funds that are payable within one year of not less than $2,000. The Company was in compliance with this financial covenant as of December 31, 2016.

Warranty

The Company offers a warranty on all of its non-disposable products of one to two years. The Company warrants disposable products through their expiration date. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary.

Page 10

Table of Contents

The warranty liability is included in other current liabilities in the unaudited balance sheet. The change in the warranty liability for the six months ended December 31, 2016 is summarized in the following table:

Balance at July 1, 2016	$	566
Warranties issued during the period		59
Settlements made during the period		(67	)
Changes in liability for pre-existing warranties during the period		(5	)
Balance at December 31, 2016	$	553

Employee Agreements and Company Policy

As of December 31, 2016, certain of the Company’s key executives have rights upon termination under employment agreements or current company policy. The agreements and company policy provide, among other things, for the payment of twelve months of severance compensation for termination under certain circumstances. With respect to these agreements and policy at December 31, 2016, potential severance, including incentive compensation amounted to $506.

On November 3, 2016, the Company’s Chief Executive Officer (“CEO”) was replaced. In accordance with his employment agreement, he was paid approximately $1.4 million for severance and other benefits plus the acceleration of vesting of his stock options and restricted stock (see Note 7). The severance portion of the expense of $1.2 million was recorded during the quarter ended December 31, 2016 and paid in January 2017.

5. Convertible Debentures

In February 2016 in exchange for aggregate proceeds of $15 million, the Company sold and issued to Boyalife Investment Inc. and Boyalife (Hong Kong) Limited (i) 735,294 shares of common stock at a purchase price of $3.40 per share (the “Stock Price”) for gross proceeds of $2.5 million, (ii) Secured Convertible Debentures for $12.5 million (the “Debentures”) convertible into 3,676,471 shares of common stock and (iii) warrants to purchase 3,529,412 additional shares of common stock at an exercise price of $8.00 per share for a period of five years. The amount of warrants was based on 80% coverage of the shares issued or to be issued for the equity transaction in (i) and the debt transaction in (ii) above. The warrants were exercisable on August 13, 2016 and are outstanding at December 31, 2016.

On August 22, 2016, the Company notified Boyalife Investment Inc., that the Company elected to convert all outstanding principal and interest accrued and otherwise payable under the Debentures, which included the conversion of $12,500 of principal and $8,250 of interest up to and including the maturity date of the Debentures. Upon conversion, 6,102,941 shares of common stock were issued and the Debentures and all security interest and liens were terminated. The common shares of 2,426,470 that were issued for payment of the interest, had a fair market value of $11,404 on August 22, 2016. Accordingly, an additional $3,154 of interest expense was recorded on the date of conversion.

At the time of the conversion, the remaining debt discount of $9,538 and debt issue costs of $155 were fully amortized.

Page 11

Table of Contents

6. Derivative Obligations

Series A Warrants

Series A warrants to purchase 404,410 common shares were issued and vested during the year ended June 30, 2016. At the time of issuance, the Company determined that as such warrants can be settled for cash at the holders’ option in a future fundamental transaction which constituted a derivative liability. The Company has estimated the fair value of the derivative liability, using a Binomial Lattice Valuation Model and the following assumptions:

	Series A
	December 31, 2016			June 30, 2016
Market price of common stock	$	3.45		$	2.93
Expected volatility		106	%		99	%
Contractual term (years)		4.2			4.7
Discount rate		1.73	%		1.01	%
Dividend rate		0	%		0	%
Exercise price	$	8.00		$	8.00

Expected volatilities are based on the historical volatility of the Company’s common stock. Contractual term is based on remaining term of the respective warrants. The discount rate represents the yield on U.S. Treasury bonds with a maturity equal to the contractual term.

The Company recorded a gain of $153 and $2,180 during the three months ended December 31, 2016 and 2015, respectively and a (loss) gain of ($174) and $3,606 during the six months ended December 31, 2016 and 2015, respectively, representing the net change in the fair value of the derivative liability, which is presented as fair value change of derivative instruments, in the accompanying condensed consolidated statements of operations and comprehensive loss.

The following table represents the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of December 31, 2016 and June 30, 2016:

Balance at

December 31, 2016

Level 1

Level 2

Level 3

Derivative obligation

844

Balance at

June 30, 2016

Level 1

Level 2

Level 3

Derivative obligation

670

The following table reflects the change in fair value of the Company’s derivative liabilities for the six months ended December 31, 2016:

	Amount
Balance – July 1, 2016	$	670
Change in fair value of derivative obligation		174
Balance – December 31, 2016	$	844

Page 12

Table of Contents

7. Stockholders’ Equity

Common Stock

On August 3, 2016, the Company sold 600,000 shares of common stock at a price of $4.10 per share. The net proceeds to the Company from the sale and issuance of the shares, after deducting the offering expenses borne by the Company of $369, were $2,091.

In July 2016, the compensation committee of the board of directors granted 118,288 shares of fully vested common stock to employees in partial payment of their earned amounts under the Company’s 2016 short term incentive plan. The election was made by some of the employees to satisfy the applicable federal income tax withholding obligation by a net share settlement, pursuant to which the Company withheld 46,879 shares and used the deemed proceeds from those shares to pay the income tax withholding. The net share settlement is deemed to be a repurchase by the Company of its common stock.

Stock Based Compensation

The Company recorded stock-based compensation of $735 and $1,033 for the three and six months ended December 31, 2016, and ($39) and $304 for the three and six months ended December 31, 2015.

Upon the separation with the Company’s CEO in November 2016, in accordance with his employment agreement, all outstanding options and restricted stock awards immediately vested. As a result, the Company recognized $539 of stock compensation expense in general and administrative as the vesting accelerated on 72,496 options and 79,720 restricted stock awards. Additionally, the terms of the options were modified upon the CEO’s termination such that the options were deemed to be exercisable for the entire period of the option versus expiring 90 days from the date of termination. There was no incremental compensation cost recorded for this modification as the fair-value-based measure of the modified award on the date of modification was less than the fair-value-based measure of the original award immediately before the modification.

The following is a summary of option activity for the Company’s stock option plans:

	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life		Aggregate Intrinsic Value

Outstanding at June 30, 2016		104,378		$	14.85

Granted		223,825		$	2.93
Forfeited		(3,835	)	$	16.15
Expired		(2,500	)	$	18.46

Outstanding at December 31, 2016		321,868		$	6.52		6.3	$	129

Vested and Expected to Vest at December 31, 2016		285,743		$	6.88		6.2	$	111

Exercisable at December 31, 2016		157,553		$	9.58		5.9	$	49

Page 13

Table of Contents

In December 2016, the compensation committee of the board of directors granted 50,000 options to the Company’s interim CEO. The options have an exercise price of $2.91, the closing price on the date of grant, they vest in five equal installments on each of December 16, 2016, February 4, 2017, May 4, 2017, August 4, 2017 and November 4, 2017 and have a seven year life. As the options were granted out of the 2016 Equity Incentive Plan (“2016 Plan”), they will not be exercisable until the 2016 Plan is approved by the stockholders, which approval must be received by July 7, 2017.

On July 7, 2016, the compensation committee of the board of directors granted 156,100 options to various employees. The options have an exercise price of $2.86, the closing price on the date of grant, they vest ratably every six months over a three year period and have a seven year life. As the options were granted out of the 2016 Equity Incentive Plan (“2016 Plan”), they will not be exercisable until the 2016 Plan is approved by the stockholders, which approval must be received by July 7, 2017.

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were no options exercised during the six months ended December 31, 2016 and 2015.

The fair value of the Company’s stock options granted for the six months ended December 31, 2016 was estimated using the following weighted-average assumptions:

Expected life (years)	4.2
Risk-free interest rate	1.1	%
Expected volatility	102.7	%
Dividend yield	0	%

At December 31, 2016, the total compensation cost related to options granted but not yet recognized was $259 which will be amortized over a weighted-average period of approximately two years.

Common Stock Restricted Units

The following is a summary of restricted stock activity during the six months ended December 31, 2016:

				Weighted Average
	Number of Shares			Grant Date Fair Value
Balance at June 30, 2016		63,566		$	14.96
Granted		98,417		$	4.97
Vested		(95,902	)	$	10.85
Forfeited		(933	)	$	26.37
Outstanding at December 31, 2016		65,148		$	5.26

On July 26, 2016, the compensation committee of the board of directors granted 98,417 shares of restricted stock to eight employees. The shares will fully vest on July 1, 2017 provided that the individual is employed by the Company as of such date. If the employee is terminated without cause prior to July 1, 2017 the shares vest immediately. Two of the eight employees were terminated during the quarter ended December 31, 2016, as such, 35,902 shares vested.

Page 14

Table of Contents

Warrants

A summary of warrant activity for the six months ended December 31, 2016 follows:

	Number of Shares		Weighted- Average Exercise Price Per Share
Beginning balance		4,828,721	$	9.37
Warrants granted		--		--
Warrants canceled		--		--
Warrants exercised		--		--

Outstanding at December 31, 2016		4,828,721	$	9.37

Exercisable at December 31, 2016		4,130,192	$	9.60

At December 31, 2016, the total intrinsic value of warrants outstanding and exercisable was $0.

Page 15

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This report contains forward-looking statements. The forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained herein. When used in this report, the words "anticipate," "believe," "estimate," "expect" and similar expressions as they relate to the Company or its management are intended to identify such forward-looking statements. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by these forward-looking statements. We wish to caution readers of the important factors, among others, that in some cases have affected, and in the future could affect our actual results and could cause actual results for fiscal year 2017 and beyond, to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company. These factors include without limitation, the ability to obtain capital and other financing in the amounts and at the times needed to complete clinical trials and product marketing for new products, market acceptance of new products, regulatory approval and time frames for such approval of new products and new claims for existing products, realization of forecasted income and expenses, initiatives by competitors, price pressures, failure to meet The Food and Drug Administration (“FDA”) regulations governing our products and operations and recalls associated with such regulations, the risks associated with initiating manufacturing for new products, failure to meet The Foreign Corrupt Practices Act (“FCPA”) regulations, legal proceedings, and the risk factors listed from time to time in our SEC reports, including, in particular, the factors and discussion in our Form 10-K for fiscal year 2016.

Dollars and amounts set forth below are in thousands, except share and per share amounts.

Overview

Cesca develops and markets integrated cellular therapies and delivery systems that advance the safe and effective practice of regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company was founded in 1986 and is headquartered in Rancho Cordova, California. The Company’s strategy is to continue to enhance the performance and competitiveness of its flagship product lines in the cord blood banking arena while expanding into significant new growth opportunity areas in point of care therapeutics. The Company is developing a number of offerings for the delivery of autologous cell therapies that address significant unmet medical needs and expects to partner with other pioneers in the stem cell arena to accelerate clinical evaluations, expedite regulatory approvals and penetrate the market.

On March 4, 2016, the Company affected a one (1) for twenty (20) reverse split of its issued and outstanding common stock. There were no changes to its authorized number of shares of common stock of 350,000,000. All historical share amounts disclosed herein have been retroactively recast to reflect the reverse split and subsequent share exchange.

Page 16

Table of Contents

Stem Cell Therapies

Cesca has nine cell therapies at various stages of clinical development, all but one with human data. These include critical limb ischemia (“CLI”), acute myocardial infarction (AMI), non-healing ulcers, ischemic stroke, spinal fusion, osteoarthritis, non-union fractures and avascular necrosis. The Company also has an active bone marrow transplantation (“BMT”) program. Cesca’s current emphasis is in three particular areas, as follows:

Critical Limb Ischemia (“CLI”) – On January 5, 2017, we announced that we received approval from the U.S. Food and Drug Administration (FDA) for significant revisions to our pivotal study for treatment of Critical Limb Ischemia (CLI). The CLI clinical trial is designed to demonstrate the safety and efficacy of our point-of-care SurgWerks system for the treatment of CLI patients with limited or no treatment options. The study was first approved by the FDA in June 2015, but was not initiated at that time pending funding.

The changes approved by the FDA are intended to increase patient enrollment by expanding the patient pool from Rutherford Category 5 patients only, to also include Rutherford Category 4 patients, or patients with a less severe form of the disease. In addition, the study population has been expanded to include patients who are poor candidates for either surgery or endovascular therapies, as opposed to only those patients with no viable treatment options. Finally, the FDA accepted to change the control arm from a placebo to a less invasive sham procedure. Although the primary endpoint remains Amputation Free Survival (AFS), a standard in all current CLI drug and biologic trials, the FDA recognized the need to increase the available patient population in order to properly power the clinical trial. Compared to the initial study design, the sample size was increased from 224 to 362 patients, which in turn allowed the superiority margin to be reduced from 20% to 13%. We believe that the reduced superiority margin is both achievable and clinically relevant. Due to the increased patient pool, it is expected that enrollment rates will be better than previous CLI clinical trials. Other improvements to the study include a reduction in study-related testing, improved statistical methods, and streamlined study oversight, all of which are intended to reduce costs and improve patient recruitment and investigator participation.

Acute Myocardial Infarction (“AMI”) – The SurgWerks^TM– AMI System has been designed to facilitate an adjunct treatment for patients who have suffered an acute ST-elevated myocardial infarction (“STEMI”), a particular and most threatening type of heart attack. Therapies delivered using the SurgWerks-AMI system are intended to minimize the adverse remodeling of the heart post-STEMI. The entire 4-step bedside treatment is designed to take less than 120 minutes to complete, in a single surgical procedure, in the heart catheterization laboratory of a hospital.

Bone Marrow Transplant (“BMT”) – The Company has two initiatives within its BMT program: development of the CellWerks™ technology platform for clinical and intra-laboratory use, and the delivery of BMT laboratory services through Cesca’s TotipotentRX subsidiary in India. The CellWerks Platform is designed for optimal laboratory preparation of hematopoietic stem cells to be used in BMT and bio-banking. The technology platform includes a “smart vision” control module, a corresponding disposable for processing blood and bone marrow sourced tissue and sample tracking software enabling GMP compliance. Cell analytics for laboratory and point of care use are under development and will complete the CellWerks offering. The laboratory services provided by TotipotentRX, in collaboration with Fortis Healthcare, are aimed at serving the Indian clinical market for cell therapy.

Page 17

Table of Contents

Products

Cesca’s product offerings include:

●

The SurgWerks™ System (in development) - a proprietary system comprised of the SurgWerks Processing Platform, including devices and analytics, and indication-specific SurgWerks Procedure Kits for use in regenerative stem cell therapy at the point of care for vascular and orthopedic diseases.

●

The CellWerks™ System (in development) - a proprietary cell processing system with associated analytics for intra-laboratory preparation of adult stem cells from bone marrow or blood.

●

The AutoXpress^® System (AXP^®) - a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood.

●

The MarrowXpress™ System (MXP™) - a derivative product of the AXP and its accompanying sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow.

●

The BioArchive® System - an automated cryogenic device used by cord blood banks for the cryopreservation and storage of cord blood stem cell concentrate for future use.

●

Manual Disposables include our non-AXP bag sets used for processing and freezing cord blood. They can be stored in the automated BioArchive device or in conventional dewars.

The following is management’s discussion and analysis of certain significant factors which have affected our financial condition and results of operations during the period included in the accompanying condensed consolidated financial statements.

Critical Accounting Policies

Management’s discussion and analysis of its financial condition and results of operations is based upon the condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these condensed financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. For a full discussion of our accounting estimates and assumptions that we have identified as critical in the preparation of our condensed consolidated financial statements, please refer to our 2016 Annual Report on Form 10-K.

Page 18

Table of Contents

Results of Operations for the Three Months Ended December 31, 2016 as Compared to the Three Months Ended December 31, 2015

Net Revenues

Net revenues for the three months ended December 31, 2016 were $4,005 compared to $3,294 for the three months ended December 31, 2015, an increase of $711 or 22%. The increase is primarily a result of increased shipments of AXP disposables to a single end-user customer. We do not expect this trend to continue in the third quarter.

The following represents the Company’s revenues by product platform for the three months ended:

	December 31,
	2016		2015

AXP	$	2,958	$	2,046
BioArchive		591		584
Manual Disposables		338		383
ResQ BMC and MXP		43		126
Other		75		155
	$	4,005	$	3,294

Gross Profit

The Company’s gross profit was $1,552 or 39% of net revenues for the three months ended December 31, 2016, compared to $1,028 or 31% for the corresponding fiscal 2016 period. Our gross profit margin increased primarily due to higher average sales prices on our mix of products sold. Additionally, there was an increase to our inventory reserves during the quarter ended December 31, 2015.

Sales and Marketing Expenses

Sales and marketing expenses were $294 for the three months ended December 31, 2016, compared to $527 for the comparable fiscal 2016 period, a decrease of $233 or 44%. The decrease is primarily due to lower personnel costs from voluntary and involuntary terminations.

Research and Development Expenses

Research and development expenses include costs associated with our engineering, regulatory, scientific and clinical functions.

Research and development expenses were $694 for the three months ended December 31, 2016, compared to $646 for the comparable fiscal 2016 period, an increase of $48 or 7%. The slight increase is primarily due to an overall credit in stock compensation in research and development during the quarter ended December 31, 2015 related to terminations and revaluing consultant awards. We anticipate research and development costs to increase if we initiate the CLIRST III clinical trial.

General and Administrative Expenses

General and administrative expenses include costs associated with our accounting, finance, human resources, information system and executive functions.

General and administrative expenses were $4,137 for the three months ended December 31, 2016, compared to $1,823 for the comparable fiscal 2016 period, an increase of $2,314 or 127%. The increase is primarily due to the termination of our chief executive officer in November which resulted in $1.9 million of expense for his severance, other benefits and acceleration of stock options and restricted stock units. Additionally, legal expenses increased $650 largely as a result of attorney fees associated with the SynGen litigation. This litigation is a potential gain contingency. We currently have an agreement to be reimbursed for these legal fees by our largest shareholder. Netting out the $1.9 million non-recurring severance charge and the increase in legal fees of $650, this line item decreased from the quarter ended December 31, 2015.

Page 19

Table of Contents

Non-U.S. GAAP Measures

In addition to the results reported in accordance with U.S. GAAP, we also use a non-U.S. GAAP measure, adjusted EBITDA, to evaluate operating performance and to facilitate the comparison of our historical results and trends. This financial measure is not a measure of financial performance under US GAAP and should not be considered in isolation or as a substitute for loss as a measure of performance. The calculation of this non-U.S. GAAP measure may not be comparable to similarly titled measures used by other companies. Reconciliations to the most directly comparable U.S. GAAP measure are provided below.

	Three Months Ended December 31,
	2016			2015
Loss from operations	$	(3,573	)	$	(1,968	)

Add (subtract):
Depreciation and amortization		212			294
Stock-based compensation expense		735			(39	)
Adjusted EBITDA loss	$	(2,626	)	$	(1,713	)

Adjusted EBITDA

The adjusted EBITDA loss was $2,626 for the three months ended December 31, 2016 compared to $1,713 for the three months ended December 31, 2015. The adjusted EBITDA loss increased compared to the second quarter in the prior year primarily due to the severance and other related costs during the three months ended December 31, 2016 associated with terminating our chief executive officer.

Results of Operations for the Six Months Ended December 31, 2016 as Compared to the Six Months Ended December 31, 2015

Net Revenues

Net revenues for the six months ended December 31, 2016 were $7,772 compared to $6,117 for the six months ended December 31, 2015, an increase of $1,655 or 27%. The increase is primarily a result of increased shipments of AXP disposables to a single end-user customer. Revenues from Cesca’s Res-Q product line also increased as a result of a final shipment during the first quarter of fiscal 2017 to the Company’s largest Res-Q distributor consistent with the Company’s plan to withdraw the product from the market.

The following represents the Company’s revenues by product platform for the six months ended:

	December 31,
	2016		2015

AXP	$	4,815	$	3,407
BioArchive		1,496		1,287
Manual Disposables		681		790
ResQ BMC and MXP		613		331
Other		167		302
	$	7,772	$	6,117

Page 20

Table of Contents

Gross Profit

The Company’s gross profit was $2,934 or 38% of net revenues for the six months ended December 31, 2016, compared to $1,395 or 23% for the corresponding fiscal 2016 period. Our gross profit margin increased primarily due to higher average sales prices on our mix of products sold during the six months ended December 31, 2016. Additionally, there was an increase to our inventory reserves during the six months ended December 31, 2015.

Sales and Marketing Expenses

Sales and marketing expenses were $775 for the six months ended December 31, 2016, compared to $1,159 for the comparable fiscal 2016 period, a decrease of $384 or 33%. The decrease is primarily due to lower personnel costs during the six months ended December 31, 2016 as a result of our September 2015 restructuring initiative and other attrition.

Research and Development Expenses

Research and development expenses were $1,364 for the six months ended December 31, 2016, compared to $1,743 for the comparable fiscal 2016 period, a decrease of $379 or 22%. The decrease is primarily due to lower personnel costs during the six months ended December 31, 2016 from our September 2015 restructuring initiative and other attrition and a reduction in rent expense associated with consolidation of our US operations into our Rancho Cordova facility. We anticipate research and development costs to increase if we initiate the CLIRST III clinical trial.

General and Administrative Expenses

General and administrative expenses were $6,316 for the six months ended December 31, 2016, compared to $4,375 for the comparable fiscal 2016 period, an increase of $1,941 or 44%. The increase is primarily due to the termination of our chief executive officer in November which resulted in $1.9 million of expense for his severance and acceleration of stock options and restricted stock units. Additionally, legal expenses increased $955,000 largely as a result of attorney fees associated with the SynGen litigation. This litigation is a potential gain contingency. We currently have an agreement to be reimbursed for these legal fees by our largest shareholder. Netting out the $1.9 million non-recurring severance charge and the increase in legal fees of $955, this line item decreased from the six months ended December 31, 2015.

Non-U.S. GAAP Measures

In addition to the results reported in accordance with US GAAP, we also use a non-U.S. GAAP measure, adjusted EBITDA, to evaluate operating performance and to facilitate the comparison of our historical results and trends. This financial measure is not a measure of financial performance under US GAAP and should not be considered in isolation or as a substitute for loss as a measure of performance. The calculation of this non-U.S. GAAP measure may not be comparable to similarly titled measures used by other companies. Reconciliations to the most directly comparable U.S. GAAP measure are provided below.

	Six Months Ended December 31,
	2016			2015
Loss from operations	$	(5,521	)	$	(5,882	)

Add (subtract):
Depreciation and amortization		473			659
Stock-based compensation expense		1,033			304
Adjusted EBITDA loss	$	(4,015	)	$	(4,919	)

Page 21

Table of Contents

Adjusted EBITDA

The adjusted EBITDA loss was $4,015 for the six months ended December 31, 2016 compared to $4,919 for the six months ended December 31, 2015. The adjusted EBITDA loss decreased compared to the comparable period in the prior year due to our savings realized from the September 2015 restructuring and a higher gross profit margin on our mix of products sold.

Liquidity and Capital Resources

At December 31, 2016, the Company had cash and cash equivalents of $4,899 and working capital of $5,499. This compares to cash and cash equivalents of $5,835 and working capital of $7,301 at June 30, 2016. The Company has primarily financed operations through private and public placement of equity securities.

On August 22, 2016, the Company elected to convert all outstanding principal and interest accrued and otherwise payable under Debentures aggregating $23,905 dating back to Cesca’s February 2016 financing. Upon conversion, 6,102,941 shares of common stock were issued and the Debentures plus all related security interests and liens were terminated.

The Company anticipates a need for additional funding to support its clinical programs, in particular the CLIRST III clinical trial. As such, management continues to investigate potential new sources of capital, including strategic partner relationships. Cesca cannot assure that such funding will be available, however, on a timely basis, in needed quantities, or on favorable terms, if at all.

Because of recurring and expected operating losses, our cash balance and severance payments due to the terminated chief executive officer, there is substantial doubt about our ability to continue as a going concern. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

Net cash used in operating activities for the six months ended December 31, 2016 was $2,570 compared to $4,494 for the six months ended December 31, 2015. The improvement in net cash used in operating activities was primarily due to the savings realized from the September 2015 restructuring and a higher gross profit margin on our mix of products sold.

On November 3, 2016, our Chief Executive Officer was replaced. In accordance with his employment agreement, he was paid approximately $1.4 million for severance and other benefits plus the acceleration of vesting of his stock options and restricted stock. The severance expense of $1.2 million was recorded during the quarter ended December 31, 2016 and paid in January 2017.

Off-Balance Sheet Arrangements

As of December 31, 2016, we had no off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Securities and Exchange Act of 1934 and are not required to provide information under this item.

Page 22

Table of Contents

Item 4. Controls and Procedures

Cesca carried out an evaluation, under the supervision, and with the participation, of management, including both the Company’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of Cesca’s disclosure controls and procedures (as defined by Exchange Act Rule 13a-15(e) and 15d-15(e)) as of the end of our fiscal quarter pursuant to Exchange Act Rule 13a-15. Disclosure controls and procedures cover controls and other procedures that are designed to ensure that information required to be disclosed by the Company in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon that evaluation, Cesca’s Chief Executive Officer and Chief Financial Officer have both concluded that the Company’s disclosure controls and procedures were effective as of December 31, 2016.

There were no changes in Cesca’s internal controls over financial reporting that occurred during the three months ended December 31, 2016 that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting. Management believes that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within any company, have been detected.

Page 23

Table of Contents

PART II - OTHER INFORMATION

Item 1.

Legal Proceedings.

In the normal course of operations, we may have disagreements or disputes with distributors, vendors or employees. Such potential disputes are seen by management as a normal part of business. There have been no material changes since the disclosures set forth in the Company’s 10-K for fiscal year end June 30, 2016.

Item 1A.

Risk Factors.

In addition to the risk factors discussed below and other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2016, which could materially affect our business, financial condition or future results. There have been no material changes from those risk factors, other than the risk factors listed below. The risks described in our Annual Report on Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known or knowable to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

There is doubt about our ability to continue as a going concern due to our recurring and expected operating losses and cash balance which means that we may not be able to continue operations. We cannot provide investors with the assurance that we will be able to raise sufficient funds from the generation of revenues or through financing to sustain the Company over the next twelve months. Given our cash balance and the fact that we have had recurring operating losses and expect those losses to continue, we believe there is substantial doubt about our ability to continue as a going concern.

We are a smaller reporting company, and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors. We are currently a “smaller reporting company,” meaning that we have a public float of less than $75 million. As long as we are considered a smaller reporting company, we are permitted to provide simplified executive compensation and other disclosures in our SEC filings, we will be exempt from the provisions of Section 404(b) of the Sarbanes-Oxley Act requiring that an independent registered public accounting firm provide an attestation report on the effectiveness of our internal control over financial reporting, and our disclosure obligations in SEC filings will be limited in certain other respects, including, among other things, that we are only required to provide two years of audited financial statements in annual reports. Such limited disclosures in our SEC filings due to our status as a smaller reporting company may make it harder for investors to analyze our results of operations and financial prospects.

If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, our ability to operate our business and investors’ views of us. We are required to establish and maintain adequate internal control over financial reporting, which are processes designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. We are also required to comply with Section 404 of the Sarbanes-Oxley Act of 2002, which requires public companies to conduct an annual review and evaluation of their internal control over financial reporting and to obtain attestations of the effectiveness of internal controls by independent auditors. However, as a “smaller reporting company,” we are not required to obtain an auditor attestation. If, in the future, we require an attestation report from our independent registered public accounting firm and that firm is unable to provide an unqualified attestation report on the effectiveness of our internal controls over financial reporting, investor confidence and, in turn, our stock price could be materially adversely affected.

Page 24

Table of Contents

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3.

Defaults upon Senior Securities.

None.

Item 4.

Mine Safety Disclosure.

Not applicable.

Item 5.

Other Information.

None.

Page 25

Table of Contents

Item 6.

Exhibits.

3.1	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cesca Therapeutics Inc.⁽¹⁾

3.2.1

Bylaws of Cesca Therapeutics Inc.⁽²⁾

3.2.2

Restated Bylaws of Cesca Therapeutics Inc.⁽³⁾

3.3	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cesca Therapeutics Inc.⁽⁴⁾

3.4	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cesca Therapeutics Inc.⁽⁵⁾

3.5	Certificate of Amendment to the Sixth Amended and Restated Certificate of Incorporation.⁽⁶⁾

10.1	Form of Indemnification Agreement⁽⁷⁾

10.2	General Release of Waiver dated November 7, 2016 by and between Cesca Therapeutics, Inc. and Robin Stracey⁽⁸⁾

10.3	Employment Agreement dated December 14, 2016 by and between Cesca Therapeutics Inc. and Dr. Xiaochun (Chris) Xu⁽⁹⁾

31.1	Certification by the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2	Certification by the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32	Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes Oxley Act of 2002.

101.INS

XBRL Instance Document‡

101.SCH

XBRL Taxonomy Extension Schema Document‡

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document‡

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document‡

101.LAB

XBRL Taxonomy Extension Label Linkbase Document‡

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document‡

Footnotes to Exhibit Index

(1)

Incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 25, 2015

(2)

Incorporated by reference to Exhibit 3.2.1 to Form 8-K filed on May 1, 2014

(3)

Incorporated by reference to Exhibit 3.2.2 to Form 8-K filed on October 30, 2014

(4)

Incorporated by reference to Exhibit 3.3 to Form 8-K filed on August 26, 2010

(5)

Incorporated by reference to Exhibit 3.5 to Form 8-K filed on November 5, 2015

(6)

Incorporated by reference to Exhibit 3.1 to Form 8-K filed on March 4, 2016

(7)

Incorporated by reference to Exhibit 10.1 to Form 8-K/A filed on November 17, 2016

(8)

Incorporated by reference to Exhibit 10.2 to Form 8-K/A filed on November 17, 2016

(9)

Incorporated by reference to Exhibit 10.1 to Form 8-K filed on December 20, 2016

‡

XBRL information is furnished and not filed for purpose of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement or prospectus to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document.

Page 26

Table of Contents

Cesca Therapeutics Inc.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		Cesca Therapeutics Inc. (Registrant)



Dated: February 13, 2017	By:	/s/ Dr. Xiaochun (Chris) Xu
		Dr. Xiaochun (Chris) Xu Interim Chief Executive Officer (Principal Executive Officer)



Dated: February 13, 2017	By:	/s/ Michael R. Bruch
		Michael R. Bruch Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

Page 27

EX-31.1 2 ex31-1.htm EXHIBIT 31.1 ex31-1.htm

Exhibit 31.1

PRINCIPAL EXECUTIVE OFFICER’S CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Xiaochun (Chris) Xu, certify that:

1. I have reviewed this report on Form 10-Q of Cesca Therapeutics Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusion about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: February 13, 2017

/s/ Dr. Xiaochun (Chris) Xu

Dr. Xiaochun (Chris) Xu

Interim Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 ex31-2.htm EXHIBIT 31.2 ex31-2.htm

Exhibit 31.2

PRINCIPAL FINANCIAL OFFICER’S CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael R. Bruch, certify that:

1. I have reviewed this report on Form 10-Q of Cesca Therapeutics Inc.;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: February 13, 2017

/s/ Michael R. Bruch

Michael R. Bruch

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

EX-32 4 ex32.htm EXHIBIT 32 ex32.htm

Exhibit 32

This certification accompanies this report and is being furnished pursuant to Item 601(b)(32) of Regulation S-K promulgated under the Securities Act of 1933, as amended (the “Securities Act”) and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. This certification shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed “filed” by the Registrant for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, or incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Registrant specifically incorporates it by reference into such a filing.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Cesca Therapeutics Inc. (the "Company") on Form 10-Q for the period ended December 31, 2016, as filed with the Securities and Exchange Commission (the "Report"), we, Dr. Xiaochun (Chris) Xu, Interim Chief Executive Officer and Michael R. Bruch, Chief Financial Officer, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of our knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 13, 2017		/s/ Dr. Xiaochun (Chris) Xu
		Dr. Xiaochun (Chris) Xu Interim Chief Executive Officer (Principal Executive Officer)



Dated: February 13, 2017		/s/ Michael R. Bruch
		Michael R. Bruch Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

A signed original of this written certification required by section 906 has been provided to us and will be retained by us and furnished to the Securities and Exchange Commission upon request.

EX-101.INS 5 kool-20161231.xml EXHIBIT 101.INS false --06-30 Q2 2017 2016-12-31 10-Q 0000811212 9886402 Yes Smaller Reporting Company CESCA THERAPEUTICS INC. No No kool 3154000 -39000 0 9.37 9.37 3676471 8250000 12500000 4282000 -564000 -564000 15000000 -59000 311000 P21Y 5 0.8 P1Y P1Y P2Y 506000 P180D 4130192 9.60 P90D 2000000 1400000 P5Y 5499000

2059000

2648000

3019000

3169000

-37000

215795000

188569000

735000

1033000

304000

57000

49000

9538000

10011000

62000

155000

39000

9851000

52000

404412

404410

698529

197242

384191

3725782

252620

321868

146838

65148

59854

5215737

2548096

47873000

49899000

10941000

12843000

4899000

5835000

3357000

2942000

-936000

-415000

3529412

404410

0.001

150000000

350000000

9886402

3010687

9886402

3010687

10000

3000

-3401000

-623000

-25844000

-4045000

2489000

2453000

2266000

4838000

4722000

11404000

6102941

2426470

12500000

402000

783000

7641000

473000

659000

153000

2180000

-174000

3606000

670000

844000

670000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.</div>     </div><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-weight: bold;">Stockholders’ Equity</div></div><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-weight: bold;"> </div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Common Stock</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company sold <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">600,000</div> shares of common stock at a price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.10</div> per share. The net proceeds to the Company from the sale and issuance of the shares, after deducting the offering expenses borne by the Company of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$369,</div> were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,091.</div>  </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the compensation committee of the board of directors granted <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">118,288</div> shares of fully vested common stock to employees in partial payment of their earned amounts under the Company’s <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> short term incentive plan. The election was made by some of the employees to satisfy the applicable federal income tax withholding obligation by a net share settlement, pursuant to which the Company withheld <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">46,879</div> shares and used the deemed proceeds from those shares to pay the income tax withholding. The net share settlement is deemed to be a repurchase by the Company of its common stock.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"> </div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Stock Based Compensation</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company recorded stock-based compensation of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$735</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,033</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">($39)</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$304</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015.</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Upon the separation with the Company’s CEO in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> in accordance with his employment agreement, all outstanding options and restricted stock awards immediately vested. As a result, the Company recognized <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$539</div> of stock compensation expense in general and administrative as the vesting accelerated on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72,496</div> options and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">79,720</div> restricted stock awards. Additionally, the terms of the options were modified upon the CEO’s termination such that the options were deemed to be exercisable for the entire period of the option versus expiring <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">90</div> days from the date of termination. There was no incremental compensation cost recorded for this modification as the fair-value-based measure of the modified award on the date of modification was less than the fair-value-based measure of the original award immediately before the modification. </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following is a summary of option activity for the Company’s stock option plans: </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Number of </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Shares</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Weighted- </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Average</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Exercise </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Price</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Weighted- </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Average </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Remaining </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Contractual </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Life</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Aggregate </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Intrinsic</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"> </td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 52%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding at June 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">104,378</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14.85</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Granted</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">223,825</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.93</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Forfeited</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,835</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16.15</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expired </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,500</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18.46</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding at December 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">321,868</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.52</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.3</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">129</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Vested and Expected to Vest at December 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">285,743</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.88</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.2</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">111</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Exercisable at December 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">157,553</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.58</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.9</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">49</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the compensation committee of the board of directors granted <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,000</div> options to the Company’s interim CEO. The options have an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.91,</div> the closing price on the date of grant, they vest in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> equal installments on each of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and have a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seven</div> year life. As the options were granted out of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Equity Incentive Plan <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(“2016</div> Plan”), they will not be exercisable until the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Plan is approved by the stockholders, which approval must be received by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the compensation committee of the board of directors granted <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">156,100</div> options to various employees. The options have an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.86,</div> the closing price on the date of grant, they vest ratably every <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months over a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> year period and have a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seven</div> year life. As the options were granted out of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Equity Incentive Plan <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(“2016</div> Plan”), they will not be exercisable until the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Plan is approved by the stockholders, which approval must be received by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div></div> options exercised during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015.</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The fair value of the Company’s stock options granted for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> was estimated using the following weighted-average assumptions:</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 81%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected life (years)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.2</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Risk-free interest rate</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.1</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected volatility</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">102.7</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Dividend yield</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> </tr> </table> </div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the total compensation cost related to options granted but not yet recognized was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$259</div> which will be amortized over a weighted-average period of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> years.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"> </div></div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Common Stock Restricted </div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Units</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following is a summary of restricted stock activity during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016:</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Weighted </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Average</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Number of</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Shares</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Grant Date </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Fair Value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 66%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance at June 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">63,566</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14.96</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Granted</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">98,417</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.97</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Vested</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(95,902</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.85 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Forfeited</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(933</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26.37</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding at December 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">65,148</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.26</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the compensation committee of the board of directors granted <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">98,417</div> shares of restricted stock to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">eight</div> employees. The shares will fully vest on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> provided that the individual is employed by the Company as of such date. If the employee is terminated without cause prior to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> the shares vest immediately. Two of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">eight</div> employees were terminated during the quarter ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> as such, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">35,902</div> shares vested. </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"></div></div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Warrants</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">A summary of warrant activity for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> follows:</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Number of</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Shares</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Weighted-</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Average </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Exercise Price </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Per Share</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Beginning balance </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,828,721</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.37</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Warrants granted</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Warrants canceled</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Warrants exercised</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding at December 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,828,721</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.37</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Exercisable at December 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,130,192</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.60</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the total intrinsic value of warrants outstanding and exercisable was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.</div></div></div></div>

-0.35

-0.30

-3.26

-1.96

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Net Loss per Share</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net loss per share is computed by dividing the net loss to common stockholders by the weighted average number of common shares outstanding. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31:</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"> </div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 95%; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 5%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 68%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Common stock equivalents of convertible debentures</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">404,412</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Vested Series A warrants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">404,410</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">404,410</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unvested Series A warrants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">698,529</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline; vertical-align: baseline; position: relative; bottom: .33em"> (1)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">698,529</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline; vertical-align: baseline; position: relative; bottom: .33em">(1)</div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Vested Series B warrants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">197,242</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unvested Series B warrants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">384,191</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Warrants – other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,725,782</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">252,620</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stock options</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">321,868</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">146,838</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Restricted stock units</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">65,148</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59,854</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,215,737</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,548,096</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> </table> </div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 4pt"> </td> <td style="WIDTH: 18pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline; vertical-align: baseline; position: relative; bottom: .33em"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1)</div></div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> close of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> financing which never occurred. The warrants will remain outstanding but unvested until they expire in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2021</div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">.</div></div></td> </tr> </table></div></div></div></div></div></div>

-1000

-7000

1621000

449000

P2Y

259000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Series A</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"> </td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">December 31,</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">June 30,</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Market price of common stock</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.45</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.93</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected volatility</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">99</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Contractual term (years)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.2</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.7</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Discount rate</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.73</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.01</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Dividend rate</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Exercise price</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.00</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.00</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> </table></div>

P4Y73D

P4Y255D

1.06

0.99

0.0173

0.0101

4137000

1823000

6316000

4375000

13195000

1552000

1028000

2934000

1395000

-587000

-626000

-149000

-1634000

-381000

-336000

1172000

-243000

-811000

-257000

67000

832000

51000

14000

13000

299000

20614000

20821000

2000

14000

10537000

21000

2763000

3593000

1372000

1437000

14211000

17626000

47873000

49899000

5442000

5542000

1911000

4688000

-2570000

-4494000

-25844000

-4021000

-3399000

-624000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Recently Adopted Accounting Pronouncements</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,</div> “<div style="display: inline; font-style: italic;">Compensation - Stock Compensation (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718);</div> Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period</div>”. The amendments in ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> apply to all reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition that affects the vesting of the award. The Company adopted ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> The Company applies the amendments in ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> prospectively to all awards granted or modified after the effective date. Adoption of the new update to ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> did not have any impact on the financial statements of the Company.  </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Recently </div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Issued</div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"> Accounting Pronouncements</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">04</div> which removes Step <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> from the goodwill impairment test. It is effective for annual and interim periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019.</div> Early adoption is permitted for interim or annual goodwill impairment test performed with a measurement date after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> The Company has not yet determined the effect that ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">04</div> will have on its results of operations, statement of financial position or financial statement disclosures.  </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> the FASB issued ASU No. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">06,</div> “<div style="display: inline; font-style: italic;">Derivatives and Hedging (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">815):</div> Contingent Put and Call Options in Debt Instruments</div>” (“ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">06”).</div> This new standard simplifies the embedded derivative analysis for debt instruments containing contingent call or put options by removing the requirement to assess whether a contingent event is related to interest rates or credit risks. This new standard will be effective for us on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> The adoption of this standard is not expected to have an impact on the Company’s financial position or results of operations.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> “<div style="display: inline; font-style: italic;">Revenue from Contracts with Customers (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606)</div></div>” (“ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09”).</div> ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> supersedes the revenue recognition requirements in ASC Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605,</div> “Revenue Recognition” and some cost guidance included in ASC Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">35,</div> "<div style="display: inline; font-style: italic;">Revenue Recognition - Construction-Type and Production-Type Contracts</div>.” The core principle of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> is that revenue is recognized when the transfer of goods or services to customers occurs in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> requires the disclosure of sufficient information to enable readers of the Company’s financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> also requires disclosure of information regarding significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> provides <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> methods of retrospective application. The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> method would require the Company to apply ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> to each prior reporting period presented. The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> method would require the Company to retrospectively apply ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> with the cumulative effect recognized at the date of initial application. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> will be effective for the Company beginning in fiscal <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> as a result of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,</div> "<div style="display: inline; font-style: italic;">Revenue from Contracts with Customers (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606):</div> Deferral of the Effective Date</div>," which was issued by the FASB in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> and extended the original effective date by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year. The Company is currently evaluating the impact of adopting the available methodologies of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14</div> upon its financial statements in future reporting periods. The Company has not yet selected a transition method. The Company is in the process of evaluating the new standard against its existing accounting policies, including the timing of revenue recognition, and its contracts with customers to determine the effect the guidance will have on its financial statements and what changes to systems and controls <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be warranted.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">There have been <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">four</div> new ASUs issued amending certain aspects of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">08,</div> "<div style="display: inline; font-style: italic;">Principal versus Agent Considerations (Reporting Revenue Gross Versus Net)</div>," was issued in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> to clarify certain aspects of the principal versus agent guidance in ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09.</div> In addition, ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,</div> "<div style="display: inline; font-style: italic;">Identifying Performance Obligations and Licensing</div>," issued in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> amends other sections of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> including clarifying guidance related to identifying performance obligations and licensing implementation. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,</div> "<div style="display: inline; font-style: italic;">Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients</div>" provides amendments and practical expedients to the guidance in ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> in the areas of assessing collectability, presentation of sales taxes received from customers, noncash consideration, contract modification and clarification of using the full retrospective approach to adopt ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09.</div> Finally, ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,</div> “<div style="display: inline; font-style: italic;">Technical Corrections and Improvements to Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606,</div> Revenue from Contracts with Customers,</div>” was issued in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> and provides elections regarding the disclosures required for remaining performance obligations in certain cases and also makes other technical corrections and improvements to the standard. With its evaluation of the impact of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> the Company will also consider the impact on its financial statements related to the updated guidance provided by these <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">four</div> new ASUs.</div></div></div></div></div></div></div></div>

5125000

2996000

8455000

7277000

-3573000

-1968000

-5521000

-5882000

78000

-2000

1000

-24000

1360000

1662000

284000

1284000

23000

1000

239000

-8000

10373000

134000

5000

369000

276000

602000

0.001

2000000

260000

246000

4720000

2091000

566000

553000

67000

-5000

59000

3045000

2962000

-220000

-1100000

46000

27000

694000

646000

1364000

1743000

-182106000

-156262000

3.40

4005000

3294000

7772000

6117000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 95%; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 5%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 68%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Common stock equivalents of convertible debentures</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">404,412</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Vested Series A warrants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">404,410</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">404,410</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unvested Series A warrants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">698,529</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline; vertical-align: baseline; position: relative; bottom: .33em"> (1)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">698,529</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline; vertical-align: baseline; position: relative; bottom: .33em">(1)</div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Vested Series B warrants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">197,242</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unvested Series B warrants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">384,191</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Warrants – other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,725,782</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">252,620</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stock options</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">321,868</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">146,838</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Restricted stock units</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">65,148</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59,854</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,215,737</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,548,096</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Number of </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Shares</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Weighted- </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Average</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Exercise </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Price</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Weighted- </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Average </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Remaining </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Contractual </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Life</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Aggregate </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Intrinsic</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"> </td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 52%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding at June 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">104,378</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14.85</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Granted</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">223,825</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.93</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Forfeited</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,835</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16.15</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expired </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,500</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18.46</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding at December 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">321,868</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.52</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.3</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">129</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Vested and Expected to Vest at December 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">285,743</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.88</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.2</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">111</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> <td style="BACKGROUND-COLOR: #ffffff"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Exercisable at December 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">157,553</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.58</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.9</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">49</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Weighted </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Average</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Number of</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Shares</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Grant Date </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Fair Value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 66%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance at June 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">63,566</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14.96</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Granted</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">98,417</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.97</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Vested</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(95,902</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.85 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Forfeited</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(933</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26.37</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding at December 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">65,148</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.26</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Number of</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Shares</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Weighted-</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Average </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Exercise Price </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Per Share</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Beginning balance </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,828,721</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.37</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Warrants granted</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Warrants canceled</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Warrants exercised</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding at December 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,828,721</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.37</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Exercisable at December 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,130,192</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.60</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> </td> </tr> </table></div>

294000

527000

775000

1159000

1200000

1033000

304000

539000

P3Y

933

26.37

98417

4.97

63566

65148

14.96

5.26

35902

95902

10.85

1.027

0.011

4828721

157553

9.58

2500

3835

50000

156100

223825

129000

104378

321868

14.85

6.52

111000

285743

6.88

118288

18.46

16.15

2.91

2.86

2.93

3.45

2.93

72496

79720

P7Y

P4Y73D

49000

P5Y328D

P6Y109D

P6Y73D

4.10

46879

23905000

735294

600000

2500000

33662000

32273000

9849041

2069233

7932300

2048423

The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021. xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0000811212 2015-07-01 2015-12-31 0000811212 us-gaap:ConvertibleDebtSecuritiesMember 2015-07-01 2015-12-31 0000811212 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-12-31 0000811212 us-gaap:RestrictedStockUnitsRSUMember 2015-07-01 2015-12-31 0000811212 kool:UnvestedSeriesAWarrantsMember 2015-07-01 2015-12-31 0000811212 kool:UnvestedSeriesBWarrantsMember 2015-07-01 2015-12-31 0000811212 kool:VestedSeriesAWarrantsMember 2015-07-01 2015-12-31 0000811212 kool:VestedSeriesBWarrantsMember 2015-07-01 2015-12-31 0000811212 kool:WarrantOtherMember 2015-07-01 2015-12-31 0000811212 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-12-31 0000811212 kool:SeriesAWarrantMember 2015-07-01 2016-06-30 0000811212 2015-10-01 2015-12-31 0000811212 us-gaap:EmployeeStockOptionMember 2015-10-01 2015-12-31 0000811212 kool:WarrantsIssuedInConnectionWithConvertibleDebenturesMember 2016-02-01 2016-02-29 0000811212 kool:BoyalifeInvestmentIncMember 2016-02-01 2016-02-29 0000811212 kool:BoyalifeInvestmentIncMember us-gaap:ConvertibleDebtMember 2016-02-01 2016-02-29 0000811212 kool:ReverseStockSplitMember 2016-03-04 2016-03-04 0000811212 kool:ShortTermMember 2016-07-01 2016-07-31 0000811212 2016-07-01 2016-12-31 0000811212 us-gaap:ConvertibleDebtSecuritiesMember 2016-07-01 2016-12-31 0000811212 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-12-31 0000811212 us-gaap:RestrictedStockUnitsRSUMember 2016-07-01 2016-12-31 0000811212 kool:UnvestedSeriesAWarrantsMember 2016-07-01 2016-12-31 0000811212 kool:UnvestedSeriesBWarrantsMember 2016-07-01 2016-12-31 0000811212 kool:VestedSeriesAWarrantsMember 2016-07-01 2016-12-31 0000811212 kool:VestedSeriesBWarrantsMember 2016-07-01 2016-12-31 0000811212 kool:WarrantOtherMember 2016-07-01 2016-12-31 0000811212 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-12-31 0000811212 us-gaap:RestrictedStockMember 2016-07-01 2016-12-31 0000811212 kool:SeriesAWarrantMember 2016-07-01 2016-12-31 0000811212 us-gaap:MaximumMember 2016-07-01 2016-12-31 0000811212 us-gaap:MinimumMember 2016-07-01 2016-12-31 0000811212 kool:KeyExecutivesMember 2016-07-01 2016-12-31 0000811212 us-gaap:EmployeeStockOptionMember kool:The2016PlanMember 2016-07-07 2016-07-07 0000811212 kool:The2016PlanMember 2016-07-07 2016-07-07 0000811212 us-gaap:RestrictedStockMember 2016-07-26 2016-07-26 0000811212 2016-08-03 2016-08-03 0000811212 kool:ConversionOfInterestMember kool:BoyalifeInvestmentIncMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2016-08-22 2016-08-22 0000811212 kool:BoyalifeInvestmentIncMember us-gaap:ConvertibleDebtMember 2016-08-22 2016-08-22 0000811212 kool:BoyalifeInvestmentIncMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2016-08-22 2016-08-22 0000811212 2016-10-01 2016-12-31 0000811212 us-gaap:EmployeeStockOptionMember 2016-10-01 2016-12-31 0000811212 us-gaap:RestrictedStockMember 2016-10-01 2016-12-31 0000811212 us-gaap:EmployeeStockOptionMember kool:FormerChiefExecutiveOfficerMember 2016-11-01 2016-11-30 0000811212 us-gaap:RestrictedStockMember kool:FormerChiefExecutiveOfficerMember 2016-11-01 2016-11-30 0000811212 us-gaap:GeneralAndAdministrativeExpenseMember kool:FormerChiefExecutiveOfficerMember 2016-11-01 2016-11-30 0000811212 us-gaap:ChiefExecutiveOfficerMember 2016-11-03 2016-11-03 0000811212 us-gaap:EmployeeStockOptionMember kool:InterimChiefExecutiveOfficerMember 2016-12-16 2016-12-16 0000811212 2015-06-30 0000811212 2015-09-30 0000811212 2015-12-31 0000811212 kool:WarrantsIssuedInConnectionWithConvertibleDebenturesMember 2016-02-29 0000811212 kool:BoyalifeInvestmentIncMember 2016-02-29 0000811212 kool:BoyalifeInvestmentIncMember us-gaap:ConvertibleDebtMember 2016-02-29 0000811212 kool:BoyalifeInvestmentIncMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2016-02-29 0000811212 2016-03-04 0000811212 2016-06-30 0000811212 us-gaap:EmployeeStockOptionMember 2016-06-30 0000811212 us-gaap:RestrictedStockMember 2016-06-30 0000811212 kool:SeriesAWarrantMember 2016-06-30 0000811212 us-gaap:FairValueInputsLevel1Member 2016-06-30 0000811212 us-gaap:FairValueInputsLevel2Member 2016-06-30 0000811212 us-gaap:FairValueInputsLevel3Member 2016-06-30 0000811212 2016-08-03 0000811212 2016-12-31 0000811212 us-gaap:EmployeeStockOptionMember 2016-12-31 0000811212 us-gaap:RestrictedStockMember 2016-12-31 0000811212 kool:SeriesAWarrantMember 2016-12-31 0000811212 kool:SeriesAWarrantMember 2016-12-31 0000811212 us-gaap:FairValueInputsLevel1Member 2016-12-31 0000811212 us-gaap:FairValueInputsLevel2Member 2016-12-31 0000811212 us-gaap:FairValueInputsLevel3Member 2016-12-31 0000811212 2017-02-09

EX-101.SCH 6 kool-20161231.xsd EXHIBIT 101.SCH 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 007 - Document - Note 3 - Bill Payment Arrangement link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 4 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 5 - Convertible Debentures link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 6 - Derivative Obligations link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 7 - Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 4 - Commitments and Contingencies (Tables) link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 6 - Derivative Obligations (Tables) link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 7 - Stockholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 4 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 4 - Commitments and Contingencies - Changes In Product Liability Included In Accrued Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 5 - Convertible Debentures (Details Textual) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 6 - Derivative Obligations (Details Textual) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 6 - Derivative Obligations - Fair Value Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 6 - Derivative Obligations - Fair Value Hierarchy (Details) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 6 - Derivative Obligations - Change In Fair Value of Derivative Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 7 - Stockholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 7 - Stockholders' Equity - Option Activity for Stock Option Plans (Details) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 7 - Stockholders' Equity - Schedule of Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 7 - Stockholders' Equity - Restricted Stock Activity Granted to Employees (Details) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 7 - Stockholders' Equity - Warrant Activity (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 kool-20161231_cal.xml EXHIBIT 101.CAL EX-101.DEF 8 kool-20161231_def.xml EXHIBIT 101.DEF EX-101.LAB 9 kool-20161231_lab.xml EXHIBIT 101.LAB Document And Entity Information kool_PeriodOfWarrantyOnProducts Period Of Warranty On Products This line item represents the minimum period of warranty that an entity offers on all of its products. kool_ShortTermInvestmentMinimum Short Term Investment Minimum Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios, and adherence to certain clauses which must be met in order to avoid default. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants. Note To Financial Statement Details Textual us-gaap_InterestExpense Interest expense us-gaap_AmortizationOfFinancingCosts Amortization of Debt Issuance Costs statementsignificantaccountingpoliciespolicies us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Risk-free interest rate statementnote2summaryofsignificantaccountingpoliciestables statementnote4commitmentsandcontingenciestables statementnote6derivativeobligationstables statementnote7stockholdersequitytables statementnote2summaryofsignificantaccountingpoliciescalculationforbasicanddilutedearningspersharedetails statementnote4commitmentsandcontingencieschangesinproductliabilityincludedinaccruedliabilitiesdetails us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Expected volatility statementnote6derivativeobligationsfairvalueassumptionsdetails statementnote6derivativeobligationsfairvaluehierarchydetails statementnote6derivativeobligationschangeinfairvalueofderivativeliabilitiesdetails statementnote7stockholdersequityoptionactivityforstockoptionplansdetails statementnote7stockholdersequityscheduleofassumptionsdetails us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Expected life (years) (Year) us-gaap_IncreaseDecreaseInDeferredRevenue Deferred revenue Foreign currency translation adjustments statementnote7stockholdersequityrestrictedstockactivitygrantedtoemployeesdetails statementnote7stockholdersequitywarrantactivitydetails Notes To Financial Statements Notes To Financial Statements [Abstract] kool_NumberOfInstallments Number Of Installments Number of installments for vesting period. Other comprehensive income: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Accrued payroll and related expenses kool_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights Beginning balance (in dollars per share) Outstanding at December 31, 2016 (in dollars per share) The weighted average exercise price of each class of warrants or rights outstanding. kool_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber Exercisable at December 31, 2016 (in shares) The number of shares into which fully or partially vested non-option equity exercisable as of the balance sheet date. Changes in liability for pre-existing warranties during the period us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Forfeited, Weighted Average Grant Date Fair Value (in dollars per share) us-gaap_ProductWarrantyAccrualPayments Settlements made during the period kool_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice Warrants granted (in dollars per share) Weighted average price at which grantees can acquire the shares reserved for issuance on warrants awarded. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Balance, Weighted Average Grant Date Fair Value, (in dollars per share) Outstanding, Weighted Average Grant Date Fair Value, (in dollars per share) kool_ShareBasedCompensationByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice Exercisable at December 31, 2016 (in dollars per share) The weighted average exercise price of each class of exercisable warrants or rights. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Granted, Weighted Average Grant Date Fair Value (in dollars per share) Warranties issued during the period us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Vested, Weighted Average Grant Date Fair Value (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Balance, Number of Shares, (in shares) Outstanding, Number of Shares, (in shares) us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Forfeited, Number of Shares (in shares) Accounting Policies [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Granted, Number of Shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Vested, Number of Shares (in shares) (Recovery of) reserve for excess and slow-moving inventories The amount of change in the reserve for inventory. us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Vested and Expected to Vest, weighted average remaining contractual life, options (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Vested and Expected to Vest, weighted average exercise price, options (in dollars per share) Vested and Expected to Vest, aggregate intrinsic value, options us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Vested and Expected to Vest, options (in shares) Exercisable, aggregate intrinsic value, options us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Exercisable, weighted average exercise price, options (in dollars per share) us-gaap_ComprehensiveIncomeNetOfTax Comprehensive loss us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Exercisable, weighted average remaining contractual life, options (Year) us-gaap_IncreaseDecreaseInAccountsPayableTrade Accounts payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Exercisable, options (in shares) COMPREHENSIVE LOSS Outstanding, aggregate intrinsic value, options General and Administrative Expense [Member] Expenses: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Outstanding, weighted average remaining contractual life, options (Year) Schedule of Product Warranty Liability [Table Text Block] Preferred stock, shares outstanding (in shares) us-gaap_IncreaseDecreaseInOtherCurrentLiabilities Other current liabilities us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities Other noncurrent liabilities Common stock, shares outstanding (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, weighted average exercise price, options (in dollars per share) Outstanding, weighted average exercise price, options (in dollars per share) us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Expired, weighted average exercise price, options (in dollars per share) Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Proceeds from convertible debentures, net of financing costs Forfeited, weighted average exercise price, options (in dollars per share) Granted, weighted average exercise price, options (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber Beginning balance (in shares) Outstanding at December 31, 2016 (in shares) Income Statement Location [Domain] Income Statement Location [Axis] Maximum [Member] Warrants canceled (in shares) Minimum [Member] Range [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised Warrants exercised (in shares) Range [Domain] us-gaap_AllocatedShareBasedCompensationExpense Allocated Share-based Compensation Expense us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted Warrants granted (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Outstanding, options (in shares) Outstanding, options (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Expired, options (in shares) us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Prepaid expenses and other current assets us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number Interim Chief Executive Officer [Member] Related to the individual who is the interim CEO. us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Plan Name [Axis] Plan Name [Domain] Weighted average common shares outstanding – basic and diluted (in shares) Anti-dilutive securities (in shares) us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Market price of common stock (in dollars per share) kool_PaymentTermsSeveranceCompensation Payment Terms, Severance Compensation The length of the term associated with the severance payments. us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Net revenues Basic and diluted net loss per common share (in dollars per share) Award Type [Axis] Equity Award [Domain] kool_PotentialSeveranceCosts Potential Severance Costs The amount of the potential severance costs. Per share data: us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations Payments on capital lease obligations Scenario, Unspecified [Domain] Related Party [Domain] kool_SharebasedCompensationArrangementBySharebasedPaymentAwardPreModificationOfAgreement Share-based Compensation Arrangement by Share-based Payment Award, Pre-Modification of Agreement Represents the term of expiration for options exercisable from the date of termination before a modification of the share-based compensation agreement. Scenario [Axis] Related Party [Axis] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Related Party Transactions Disclosure [Text Block] us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Fair Value of Financial Instruments, Policy [Policy Text Block] Segment Reporting, Policy [Policy Text Block] Statement [Table] us-gaap_SaleOfStockPricePerShare Sale of Stock, Price Per Share Commitments and Contingencies Disclosure [Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Forfeited, options (in shares) Earnings Per Share, Policy [Policy Text Block] us-gaap_IncreaseDecreaseInInventories Inventories Granted, options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Other noncurrent liabilities Income Statement [Abstract] Cash flows from financing activities: us-gaap_StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues us-gaap_StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders’ equity Noncurrent deferred tax liability Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Accumulated deficit Retained Earnings (Accumulated Deficit) Derivative obligation Balance Balance Accumulated other comprehensive loss Derivative Contract [Domain] Derivative Instrument [Axis] Chief Executive Officer [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Vested Series B Warrants [Member] Information about the vested series B warrants. Unvested Series B Warrants [Member] Information about the unvested series B warrants. Loss on cashless exercise of warrants Loss on cashless exercise of warrants The aggregate net gain (loss) on cashless exercise of warrants. Convertible Debt [Member] Boyalife Investment Inc. [Member] Represents the legal entity, Boyalife Investment Inc. and Boyalife (Hong Kong Limited). kool_GrossProceedsFromFinancingTransaction Gross Proceeds from Financing Transaction Gross amount from issuance of combination of common stock, senior secured convertible debt and warrants to purchase additional commons stock. Title of Individual [Axis] Relationship to Entity [Domain] Short Term Plan [Member] Represents the Short Term Plan. kool_ClassOfWarrantOrRightExercisableIntrinsicValue Class of Warrant or Right, Exercisable, Intrinsic Value Amount of difference between fair value of the warrant and exercise price of vested portions of options outstanding and currently exercisable. kool_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRatableVestingPeriod Share-based Compensation Arrangement by Share-based Payment Award, Award Ratable Vesting Period In a vesting system by which awards vest ratably, the recurring period in which a portion of granted awards vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Class of Warrant or Right [Domain] Class of Warrant or Right [Axis] us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights us-gaap_ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding Net change in operating assets and liabilities: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights Former Chief Executive Officer [Member] Former highest ranking executive officer, who has ultimate managerial responsibility for the entity and who reports to the board of directors. Convertible debentures, net us-gaap_PaidInKindInterest Non-cash accrued interest us-gaap_LiabilitiesCurrent Total current liabilities Other current liabilities kool_WorkingCapital Working Capital A measure of both a company's efficiency and its short-term financial health. The working capital is calculated as: Working Capital= Current Asset - Current Liabilities. Class of Stock [Axis] us-gaap_ShareBasedCompensation Stock based compensation expense kool_DebtConversionConvertibleShares Debt Conversion, Convertible Shares The number of shares convertible upon the issuance of convertible debt. Deferred revenue Other assets us-gaap_AmortizationOfFinancingCostsAndDiscounts Amortization of debt discount Revenue Recognition, Policy [Policy Text Block] Amortization of debt discount and issue costs Amortization of Debt Discount (Premium) Counterparty Name [Domain] Common stock, $0.001 par value;150,000,000 shares authorized; 9,886,402 issued and outstanding (3,010,687 at June 30, 2016) us-gaap_TableTextBlock Notes Tables Counterparty Name [Axis] Common stock, shares issued (in shares) Warrants Issued in Connection with Convertible Debentures [Member] Represents the warrants issued in connection with convertible debentures. Conversion of Interest [Member] Represents information related to the conversion of the amount of the cost of borrowed funds accounted for as interest expense for debt. Common stock, shares authorized (in shares) Common Stock, Shares Authorized Amendment Flag us-gaap_DepreciationDepletionAndAmortization Depreciation and amortization Common stock, par value (in dollars per share) Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] kool_TerminationCostsTotal Termination Costs, Total Total expenses comprised of severance charges, other benefits, and the acceleration/vesting of stock related to the termination of certain employment agreements. EX-101.PRE 10 kool-20161231_pre.xml EXHIBIT 101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Dec. 31, 2016	Feb. 09, 2017
Document Information [Line Items]
Entity Registrant Name	CESCA THERAPEUTICS INC.
Entity Central Index Key	0000811212
Trading Symbol	kool
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		9,886,402
Document Type	10-Q
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Amendment Flag	false

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016
Current assets:
Cash and cash equivalents	$ 4,899	$ 5,835
Accounts receivable, net of allowance for doubtful accounts of $57 ($49 at June 30, 2016)	3,019	3,169
Inventories, net of reserves of $1,372 ($1,437 at June 30, 2016)	2,763	3,593
Prepaid expenses and other current assets	260	246
Total current assets	10,941	12,843
Equipment at cost, less accumulated depreciation	3,045	2,962
Goodwill	13,195	13,195
Intangible assets, net	20,614	20,821
Other assets	78	78
Total assets	47,873	49,899
Current liabilities:
Accounts payable	2,059	2,648
Accrued payroll and related expenses	1,621	449
Deferred revenue	402	783
Other current liabilities	1,360	1,662
Total current liabilities	5,442	5,542
Noncurrent deferred tax liability	7,641	7,641
Derivative obligation	844	670
Convertible debentures, net		2,489
Other noncurrent liabilities	284	1,284
Total liabilities	14,211	17,626
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none issued and outstanding
Common stock, $0.001 par value;150,000,000 shares authorized; 9,886,402 issued and outstanding (3,010,687 at June 30, 2016)	10	3
Paid in capital in excess of par	215,795	188,569
Accumulated deficit	(182,106)	(156,262)
Accumulated other comprehensive loss	(37)	(37)
Total stockholders’ equity	33,662	32,273
Total liabilities and stockholders’ equity	$ 47,873	$ 49,899

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016
Accounts Receivable, Allowance for Doubtful Accounts	$ 57	$ 49
Inventories, Reserves	$ 1,372	$ 1,437
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	9,886,402	3,010,687
Common stock, shares outstanding (in shares)	9,886,402	3,010,687

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Net revenues	$ 4,005	$ 3,294	$ 7,772	$ 6,117
Cost of revenues	2,453	2,266	4,838	4,722
Gross profit	1,552	1,028	2,934	1,395
Expenses:
Sales and marketing	294	527	775	1,159
Research and development	694	646	1,364	1,743
General and administrative	4,137	1,823	6,316	4,375
Total operating expenses	5,125	2,996	8,455	7,277
Loss from operations	(3,573)	(1,968)	(5,521)	(5,882)
Fair value change of derivative instruments	153	2,180	(174)	3,606
Amortization of debt discount		(39)	(9,851)	(52)
Interest expense	(2)	(14)	(10,537)	(21)
Registration rights liquidated damages		(220)		(1,100)
Loss on cashless exercise of warrants		(564)		(564)
Other income and (expenses)	23	1	239	(8)
Net loss	(3,399)	(624)	(25,844)	(4,021)
COMPREHENSIVE LOSS
Net loss	(3,399)	(624)	(25,844)	(4,021)
Other comprehensive income:
Foreign currency translation adjustments	(2)	1		(24)
Comprehensive loss	$ (3,401)	$ (623)	$ (25,844)	$ (4,045)
Per share data:
Basic and diluted net loss per common share (in dollars per share)	$ (0.35)	$ (0.30)	$ (3.26)	$ (1.96)
Weighted average common shares outstanding – basic and diluted (in shares)	9,849,041	2,069,233	7,932,300	2,048,423

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (25,844,000)	$ (4,021,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	473,000	659,000
Stock based compensation expense	1,033,000	304,000
(Recovery of) reserve for excess and slow-moving inventories	(59,000)	311,000
Amortization of debt discount and issue costs	10,011,000	62,000
Change in fair value of derivative	174,000	(3,606,000)
Non-cash accrued interest	10,373,000
Loss on cashless exercise of warrants		564,000
Net change in operating assets and liabilities:
Accounts receivable	149,000	1,634,000
Inventories	811,000	257,000
Prepaid expenses and other current assets	(13,000)	(299,000)
Accounts payable	(587,000)	(626,000)
Accrued payroll and related expenses	1,172,000	(243,000)
Deferred revenue	(381,000)	(336,000)
Other current liabilities	67,000	832,000
Other noncurrent liabilities	51,000	14,000
Net cash used in operating activities	(2,570,000)	(4,494,000)
Net cash used in investing activities:
Capital expenditures	(276,000)	(602,000)
Cash flows from financing activities:
Proceeds from issuance of common stock, net	2,091,000
Proceeds from convertible debentures, net of financing costs		4,720,000
Payments on capital lease obligations	(46,000)	(27,000)
Repurchase of common stock	(134,000)	(5,000)
Net cash provided by financing activities	1,911,000	4,688,000
Effects of foreign currency rate changes on cash and cash equivalents	(1,000)	(7,000)
Net decrease in cash and cash equivalents	(936,000)	(415,000)
Cash and cash equivalents at beginning of period	5,835,000	3,357,000
Cash and cash equivalents at end of period	4,899,000	2,942,000
Supplemental non-cash financing and investing information:
Derivative obligation related to issuance of warrants		4,282,000
Common stock issued for payment of convertible debentures and interest	$ 23,905,000

XML 16 R6.htm IDEA: XBRL DOCUMENT

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Basis of Presentation and Summary of Significant Accounting Policies Organization and Basis of Presentation Cesca Therapeutics Inc. (“Cesca”, or the “Company”) develops and markets integrated cellular therapies and delivery systems that advance the safe and effective practice of regenerative medicine. Cesca is a leader in developing and manufacturing automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. Reverse Stock Split On March 4, 2016, the Company affected a one (1) for twenty (20) reverse split of its issued and outstanding common stock. There were no changes to its authorized number of shares of common stock of 350,000,000. All historical share amounts disclosed herein have been retroactively recast to reflect the reverse split. No fractional shares were issued; fractional shares of common stock were rounded up to the nearest whole share. Liquidity and Going Concern At December 31, 2016, the Company had cash and cash equivalents of $4,899 and working capital of $5,499. The Company has incurred recurring operating losses and as of December 31, 2016 had an accumulated deficit of $182,106. The Company has primarily financed operations through the sale of equity securities, convertible debentures and the sale of certain non-core assets. The Company will need additional funding to support its phase III Critical Limb Ischemia (“CLIRST III”) trial. As such, management has been exploring additional funding sources, primarily strategic partner relationships. The Company cannot assure that such funding will be available on a timely basis, in needed quantities, or on favorable terms, if at all. If the Company is unable to generate sufficient revenues or obtain additional funds for its working capital needs, the Company will have to further scale-back operations. Because of recurring and expected operating losses and its cash balance there is substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. Principles of Consolidation The consolidated financial statements include the accounts of Cesca and its wholly-owned subsidiaries, TotipotentRX Cell Therapy, Pvt. Ltd. and TotipotentSC Scientific Product Pvt. Ltd. All significant intercompany accounts and transactions have been eliminated upon consolidation. Interim Reporting The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10 -Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (SEC) rules and regulations and accounting principles applicable for interim periods. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed consolidated financial statements through the date of issuance. Operating results for the six month period ended December 31, 2016, are not necessarily indicative of the results that may be expected for the year ending June 30, 2017. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Annual Report on Form 10 -K for the fiscal year ended June 30, 2016.

XML 17 R7.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies

6 Months Ended

Dec. 31, 2016

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

Summary of Significant Accounting Policies

Revenue Recognition

may

indicate that the sale to the distributor is not substantive. The Company currently recognizes revenue primarily on the sell-in method with its distributors.

years.

All other service revenue is recognized at the time the service is completed.

Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.

Fair Value Measurements

In accordance with ASC

820,

“

Fair Value Measurements and Disclosures

,” fair value is defined as the exit price, or the amount that would be received for the sale of an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date.

three

levels of inputs that

may

be used to measure fair value:

Level

Quoted market prices in active markets for identical assets or liabilities.

Level

Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level

Unobservable inputs reflecting the reporting entity’s own assumptions.

within the fair value hierarchy since the valuation model of the derivative obligation is based on unobservable inputs.

Segment Reporting

The Company has

one

reportable business segment: the research, development and commercialization of autologous cell-based therapies for use in regenerative medicine.

Net Loss per Share

December

31:

	2016			2015
Common stock equivalents of convertible debentures		--			404,412
Vested Series A warrants		404,410			404,410
Unvested Series A warrants		698,529	(1)		698,529	(1)
Vested Series B warrants		--			197,242
Unvested Series B warrants		--			384,191
Warrants – other		3,725,782			252,620
Stock options		321,868			146,838
Restricted stock units		65,148			59,854
Total		5,215,737			2,548,096

(1)

The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the

second

close of the

August

2015

financing which never occurred. The warrants will remain outstanding but unvested until they expire in

February

2021

Reclassifications

Certain reclassifications have been made from the fiscal

2016

amounts to conform to the fiscal

2017

presentation. These reclassifications did not have any effect on our net loss or stockholders’ equity.

Recently Adopted Accounting Pronouncements

June

2014,

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No.

2014

12,

“

Compensation - Stock Compensation (Topic

718);

Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period

”. The amendments in ASU

2014

apply to all reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition that affects the vesting of the award. The Company adopted ASU

2014

effective

July

2016.

The Company applies the amendments in ASU

2014

prospectively to all awards granted or modified after the effective date. Adoption of the new update to ASU

2014

did not have any impact on the financial statements of the Company.

Recently

Issued

Accounting Pronouncements

January

2017,

the FASB issued ASU

2017

which removes Step

from the goodwill impairment test. It is effective for annual and interim periods beginning after

December

15,

2019.

Early adoption is permitted for interim or annual goodwill impairment test performed with a measurement date after

January

2017.

The Company has not yet determined the effect that ASU

2017

will have on its results of operations, statement of financial position or financial statement disclosures.

March

2016

the FASB issued ASU No.

2016

06,

“

Derivatives and Hedging (Topic

815):

Contingent Put and Call Options in Debt Instruments

” (“ASU

2016

06”).

This new standard simplifies the embedded derivative analysis for debt instruments containing contingent call or put options by removing the requirement to assess whether a contingent event is related to interest rates or credit risks. This new standard will be effective for us on

January

2017.

The adoption of this standard is not expected to have an impact on the Company’s financial position or results of operations.

May

2014,

the FASB issued ASU

2014

09,

“

Revenue from Contracts with Customers (Topic

606)

” (“ASU

2014

09”).

ASU

2014

supersedes the revenue recognition requirements in ASC Topic

605,

“Revenue Recognition” and some cost guidance included in ASC Subtopic

605

35,

Revenue Recognition - Construction-Type and Production-Type Contracts

.” The core principle of ASU

2014

is that revenue is recognized when the transfer of goods or services to customers occurs in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASU

2014

requires the disclosure of sufficient information to enable readers of the Company’s financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. ASU

2014

also requires disclosure of information regarding significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU

2014

provides

two

methods of retrospective application. The

first

method would require the Company to apply ASU

2014

to each prior reporting period presented. The

second

method would require the Company to retrospectively apply ASU

2014

with the cumulative effect recognized at the date of initial application. ASU

2014

will be effective for the Company beginning in fiscal

2019

as a result of ASU

2015

14,

Revenue from Contracts with Customers (Topic

606):

Deferral of the Effective Date

," which was issued by the FASB in

August

2015

and extended the original effective date by

one

year. The Company is currently evaluating the impact of adopting the available methodologies of ASU

2014

and

2015

upon its financial statements in future reporting periods. The Company has not yet selected a transition method. The Company is in the process of evaluating the new standard against its existing accounting policies, including the timing of revenue recognition, and its contracts with customers to determine the effect the guidance will have on its financial statements and what changes to systems and controls

may

be warranted.

There have been

four

new ASUs issued amending certain aspects of ASU

2014

09,

ASU

2016

08,

Principal versus Agent Considerations (Reporting Revenue Gross Versus Net)

," was issued in

March,

2016

to clarify certain aspects of the principal versus agent guidance in ASU

2014

09.

In addition, ASU

2016

10,

Identifying Performance Obligations and Licensing

," issued in

April

2016,

amends other sections of ASU

2014

including clarifying guidance related to identifying performance obligations and licensing implementation. ASU

2016

12,

Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients

" provides amendments and practical expedients to the guidance in ASU

2014

in the areas of assessing collectability, presentation of sales taxes received from customers, noncash consideration, contract modification and clarification of using the full retrospective approach to adopt ASU

2014

09.

Finally, ASU

2016

20,

“

Technical Corrections and Improvements to Topic

606,

Revenue from Contracts with Customers,

” was issued in

December

2016,

and provides elections regarding the disclosures required for remaining performance obligations in certain cases and also makes other technical corrections and improvements to the standard. With its evaluation of the impact of ASU

2014

09,

the Company will also consider the impact on its financial statements related to the updated guidance provided by these

four

new ASUs.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Note 3 - Bill Payment Arrangement	6 Months Ended
Note 3 - Bill Payment Arrangement	Dec. 31, 2016
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	3. Bill Payment Arrangement The Company entered into a bill payment arrangement whereby Boyalife Group Ltd. (“Payor”), the Company's largest shareholder, will pay the Company’s legal expenses payable to the Company’s attorney related to certain litigation involving SynGen Inc. (the “Bill Payment Arrangement”), although the Company will remain jointly and severally liable for the payment of such legal fees. The terms of the Bill Payment Arrangement provide that the Company will reimburse Payor for any and all amounts paid by Payor in connection with the Bill Payment Arrangement under certain specified events. Any amounts received from Payor will be recorded as a liability until which time such liability has been adjudicated.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Note 4 - Commitments and Contingencies

6 Months Ended

Dec. 31, 2016

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

Commitments and Contingencies

Financial Covenants

Effective

September

30,

2015,

the Company entered into a Fifth Amended and Restated Technology License and Escrow Agreement with Cord Blood Registry Systems, Inc. which modified the financial covenant that the Company must meet in order to avoid an event of default. The Company must maintain a cash balance and short-term investments net of debt or borrowed funds that are payable within

one

year of not less than

$2,000.

The Company was in compliance with this financial covenant as of

December

31,

2016.

Warranty

The Company offers a warranty on all of its non-disposable products of

one

two

years. The Company warrants disposable products through their expiration date. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary.

The warranty liability is included in other current liabilities in the unaudited balance sheet. The change in the warranty liability for the

six

months ended

December

31,

2016

is summarized in the following table:

Balance at July 1, 2016	$	566
Warranties issued during the period		59
Settlements made during the period		(67	)
Changes in liability for pre-existing warranties during the period		(5	)
Balance at December 31, 2016	$	553

Employee Agreements

and Company Policy

As of

December

31,

2016,

certain of the Company’s key executives have rights upon termination under employment agreements or current company policy. The agreements and company policy provide, among other things, for the payment of

twelve

months of severance compensation for termination under certain circumstances. With respect to these agreements and policy at

December

31,

2016,

potential severance, including incentive compensation amounted to

$506.

November

2016,

the Company’s Chief Executive Officer (“CEO”) was replaced. In accordance with his employment agreement, he was paid approximately

$1.4

million for severance and other benefits plus the acceleration of vesting of his stock options and restricted stock (see Note

7).

The severance portion of the expense of

$1.2

million was recorded during the quarter ended

December

31,

2016

and paid in

January

2017.

XML 20 R10.htm IDEA: XBRL DOCUMENT

Note 5 - Convertible Debentures	6 Months Ended
Note 5 - Convertible Debentures	Dec. 31, 2016
Notes to Financial Statements
Debt Disclosure [Text Block]	5. Convertible Debentures In February 2016 in exchange for aggregate proceeds of $15 million, the Company sold and issued to Boyalife Investment Inc. and Boyalife (Hong Kong) Limited (i) 735,294 shares of common stock at a purchase price of $3.40 per share (the “Stock Price”) for gross proceeds of $2.5 million, (ii) Secured Convertible Debentures for $12.5 million (the “Debentures”) convertible into 3,676,471 shares of common stock and (iii) warrants to purchase 3,529,412 additional shares of common stock at an exercise price of $8.00 per share for a period of five years. The amount of warrants was based on 80% coverage of the shares issued or to be issued for the equity transaction in (i) and the debt transaction in (ii) above. The warrants were exercisable on August 13, 2016 and are outstanding at December 31, 2016. On August 22, 2016, the Company notified Boyalife Investment Inc., that the Company elected to convert all outstanding principal and interest accrued and otherwise payable under the Debentures, which included the conversion of $12,500 of principal and $8,250 of interest up to and including the maturity date of the Debentures. Upon conversion, 6,102,941 shares of common stock were issued and the Debentures and all security interest and liens were terminated. The common shares of 2,426,470 that were issued for payment of the interest, had a fair market value of $11,404 on August 22, 2016. Accordingly, an additional $3,154 of interest expense was recorded on the date of conversion. At the time of the conversion, the remaining debt discount of $9,538 and debt issue costs of $155 were fully amortized.

XML 21 R11.htm IDEA: XBRL DOCUMENT

Note 6 - Derivative Obligations

6 Months Ended

Dec. 31, 2016

Notes to Financial Statements

Derivatives and Fair Value [Text Block]

Derivative Obligations

Series A Warrants

Series A warrants to purchase

404,410

common shares were issued and vested during the year ended

June

30,

2016.

At the time of issuance, the Company determined that as such warrants can be settled for cash at the holders’ option in a future fundamental transaction which constituted a derivative liability. The Company has estimated the fair value of the derivative liability, using a Binomial Lattice Valuation Model and the following assumptions:

	Series A
	December 31, 2016			June 30, 2016
Market price of common stock	$	3.45		$	2.93
Expected volatility		106	%		99	%
Contractual term (years)		4.2			4.7
Discount rate		1.73	%		1.01	%
Dividend rate		0	%		0	%
Exercise price	$	8.00		$	8.00

The Company recorded a gain of

$153

and

$2,180

during the

three

months ended

December

31,

2016

and

2015,

respectively and a (loss) gain of

($174)

and

$3,606

during the

six

months ended

December

31,

2016

and

2015,

respectively, representing the net change in the fair value of the derivative liability, which is presented as fair value change of derivative instruments, in the accompanying condensed consolidated statements of operations and comprehensive loss.

The following table represents the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of

December

31,

2016

and

June

30,

2016:

	Balance at December 31, 2016		Level 1		Level 2		Level 3

Derivative obligation	$	844	$	-	$	-	$	844

	Balance at June 30, 2016		Level 1		Level 2		Level 3

Derivative obligation	$	670	$	-	$	-	$	670

The following table reflects the change in fair value of the Company’s derivative liabilities for the

six

months ended

December

31,

2016:

	Amount
Balance – July 1, 2016	$	670
Change in fair value of derivative obligation		174
Balance – December 31, 2016	$	844

XML 22 R12.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity

6 Months Ended

Dec. 31, 2016

Notes to Financial Statements

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Stockholders’ Equity

Common Stock

August

2016,

the Company sold

600,000

shares of common stock at a price of

$4.10

per share. The net proceeds to the Company from the sale and issuance of the shares, after deducting the offering expenses borne by the Company of

$369,

were

$2,091.

July

2016,

the compensation committee of the board of directors granted

118,288

shares of fully vested common stock to employees in partial payment of their earned amounts under the Company’s

2016

short term incentive plan. The election was made by some of the employees to satisfy the applicable federal income tax withholding obligation by a net share settlement, pursuant to which the Company withheld

46,879

shares and used the deemed proceeds from those shares to pay the income tax withholding. The net share settlement is deemed to be a repurchase by the Company of its common stock.

Stock Based Compensation

The Company recorded stock-based compensation of

$735

and

$1,033

for the

three

and

six

months ended

December

31,

2016,

and

($39)

and

$304

for the

three

and

six

months ended

December

31,

2015.

Upon the separation with the Company’s CEO in

November

2016,

in accordance with his employment agreement, all outstanding options and restricted stock awards immediately vested. As a result, the Company recognized

$539

of stock compensation expense in general and administrative as the vesting accelerated on

72,496

options and

79,720

restricted stock awards. Additionally, the terms of the options were modified upon the CEO’s termination such that the options were deemed to be exercisable for the entire period of the option versus expiring

days from the date of termination. There was no incremental compensation cost recorded for this modification as the fair-value-based measure of the modified award on the date of modification was less than the fair-value-based measure of the original award immediately before the modification.

The following is a summary of option activity for the Company’s stock option plans:

	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life		Aggregate Intrinsic Value

Outstanding at June 30, 2016		104,378		$	14.85

Granted		223,825		$	2.93
Forfeited		(3,835	)	$	16.15
Expired		(2,500	)	$	18.46

Outstanding at December 31, 2016		321,868		$	6.52		6.3	$	129

Vested and Expected to Vest at December 31, 2016		285,743		$	6.88		6.2	$	111

Exercisable at December 31, 2016		157,553		$	9.58		5.9	$	49

December

2016,

the compensation committee of the board of directors granted

50,000

options to the Company’s interim CEO. The options have an exercise price of

$2.91,

the closing price on the date of grant, they vest in

five

equal installments on each of

December

16,

2016,

February

2017,

May

2017,

August

2017

and

November

2017

and have a

seven

year life. As the options were granted out of the

2016

Equity Incentive Plan

(“2016

Plan”), they will not be exercisable until the

2016

Plan is approved by the stockholders, which approval must be received by

July

2017.

July

2016,

the compensation committee of the board of directors granted

156,100

options to various employees. The options have an exercise price of

$2.86,

the closing price on the date of grant, they vest ratably every

six

months over a

three

year period and have a

seven

year life. As the options were granted out of the

2016

Equity Incentive Plan

(“2016

Plan”), they will not be exercisable until the

2016

Plan is approved by the stockholders, which approval must be received by

July

2017.

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were

options exercised during the

six

months ended

December

31,

2016

and

2015.

The fair value of the Company’s stock options granted for the

six

months ended

December

31,

2016

was estimated using the following weighted-average assumptions:

Expected life (years)	4.2
Risk-free interest rate	1.1	%
Expected volatility	102.7	%
Dividend yield	0	%

December

31,

2016,

the total compensation cost related to options granted but not yet recognized was

$259

which will be amortized over a weighted-average period of approximately

two

years.

Common Stock Restricted

Units

The following is a summary of restricted stock activity during the

six

months ended

December

31,

2016:

				Weighted Average
	Number of Shares			Grant Date Fair Value
Balance at June 30, 2016		63,566		$	14.96
Granted		98,417		$	4.97
Vested		(95,902	)	$	10.85
Forfeited		(933	)	$	26.37
Outstanding at December 31, 2016		65,148		$	5.26

July

26,

2016,

the compensation committee of the board of directors granted

98,417

shares of restricted stock to

eight

employees. The shares will fully vest on

July

2017

provided that the individual is employed by the Company as of such date. If the employee is terminated without cause prior to

July

2017

the shares vest immediately. Two of the

eight

employees were terminated during the quarter ended

December

31,

2016,

as such,

35,902

shares vested.

Warrants

A summary of warrant activity for the

six

months ended

December

31,

2016

follows:

	Number of Shares		Weighted- Average Exercise Price Per Share
Beginning balance		4,828,721	$	9.37
Warrants granted		--		--
Warrants canceled		--		--
Warrants exercised		--		--

Outstanding at December 31, 2016		4,828,721	$	9.37

Exercisable at December 31, 2016		4,130,192	$	9.60

December

31,

2016,

the total intrinsic value of warrants outstanding and exercisable was

$0.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 23 R13.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

6 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

may

indicate that the sale to the distributor is not substantive. The Company currently recognizes revenue primarily on the sell-in method with its distributors.

years.

All other service revenue is recognized at the time the service is completed.

Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value Measurements

In accordance with ASC

820,

“

Fair Value Measurements and Disclosures

three

levels of inputs that

may

be used to measure fair value:

Level

Quoted market prices in active markets for identical assets or liabilities.

Level

Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level

Unobservable inputs reflecting the reporting entity’s own assumptions.

within the fair value hierarchy since the valuation model of the derivative obligation is based on unobservable inputs.

Segment Reporting, Policy [Policy Text Block]

Segment Reporting

The Company has

one

reportable business segment: the research, development and commercialization of autologous cell-based therapies for use in regenerative medicine.

Earnings Per Share, Policy [Policy Text Block]

Net Loss per Share

December

31:

	2016			2015
Common stock equivalents of convertible debentures		--			404,412
Vested Series A warrants		404,410			404,410
Unvested Series A warrants		698,529	(1)		698,529	(1)
Vested Series B warrants		--			197,242
Unvested Series B warrants		--			384,191
Warrants – other		3,725,782			252,620
Stock options		321,868			146,838
Restricted stock units		65,148			59,854
Total		5,215,737			2,548,096

(1)

The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the

second

close of the

August

2015

financing which never occurred. The warrants will remain outstanding but unvested until they expire in

February

2021

Reclassification, Policy [Policy Text Block]

Reclassifications

Certain reclassifications have been made from the fiscal

2016

amounts to conform to the fiscal

2017

presentation. These reclassifications did not have any effect on our net loss or stockholders’ equity.

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Adopted Accounting Pronouncements

June

2014,

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No.

2014

12,

“

Compensation - Stock Compensation (Topic

718);

Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period

”. The amendments in ASU

2014

effective

July

2016.

The Company applies the amendments in ASU

2014

prospectively to all awards granted or modified after the effective date. Adoption of the new update to ASU

2014

did not have any impact on the financial statements of the Company.

Recently

Issued

Accounting Pronouncements

January

2017,

the FASB issued ASU

2017

which removes Step

from the goodwill impairment test. It is effective for annual and interim periods beginning after

December

15,

2019.

Early adoption is permitted for interim or annual goodwill impairment test performed with a measurement date after

January

2017.

The Company has not yet determined the effect that ASU

2017

will have on its results of operations, statement of financial position or financial statement disclosures.

March

2016

the FASB issued ASU No.

2016

06,

“

Derivatives and Hedging (Topic

815):

Contingent Put and Call Options in Debt Instruments

” (“ASU

2016

06”).

January

2017.

The adoption of this standard is not expected to have an impact on the Company’s financial position or results of operations.

May

2014,

the FASB issued ASU

2014

09,

“

Revenue from Contracts with Customers (Topic

606)

” (“ASU

2014

09”).

ASU

2014

supersedes the revenue recognition requirements in ASC Topic

605,

“Revenue Recognition” and some cost guidance included in ASC Subtopic

605

35,

Revenue Recognition - Construction-Type and Production-Type Contracts

.” The core principle of ASU

2014

also requires disclosure of information regarding significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU

2014

provides

two

methods of retrospective application. The

first

method would require the Company to apply ASU

2014

to each prior reporting period presented. The

second

method would require the Company to retrospectively apply ASU

2014

with the cumulative effect recognized at the date of initial application. ASU

2014

will be effective for the Company beginning in fiscal

2019

as a result of ASU

2015

14,

Revenue from Contracts with Customers (Topic

606):

Deferral of the Effective Date

," which was issued by the FASB in

August

2015

and extended the original effective date by

one

year. The Company is currently evaluating the impact of adopting the available methodologies of ASU

2014

and

2015

may

be warranted.

There have been

four

new ASUs issued amending certain aspects of ASU

2014

09,

ASU

2016

08,

Principal versus Agent Considerations (Reporting Revenue Gross Versus Net)

," was issued in

March,

2016

to clarify certain aspects of the principal versus agent guidance in ASU

2014

09.

In addition, ASU

2016

10,

Identifying Performance Obligations and Licensing

," issued in

April

2016,

amends other sections of ASU

2014

including clarifying guidance related to identifying performance obligations and licensing implementation. ASU

2016

12,

Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients

" provides amendments and practical expedients to the guidance in ASU

2014

09.

Finally, ASU

2016

20,

“

Technical Corrections and Improvements to Topic

606,

Revenue from Contracts with Customers,

” was issued in

December

2016,

2014

09,

the Company will also consider the impact on its financial statements related to the updated guidance provided by these

four

new ASUs.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Tables)

6 Months Ended

Dec. 31, 2016

Notes Tables

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	2016			2015
Common stock equivalents of convertible debentures		--			404,412
Vested Series A warrants		404,410			404,410
Unvested Series A warrants		698,529	(1)		698,529	(1)
Vested Series B warrants		--			197,242
Unvested Series B warrants		--			384,191
Warrants – other		3,725,782			252,620
Stock options		321,868			146,838
Restricted stock units		65,148			59,854
Total		5,215,737			2,548,096

XML 25 R15.htm IDEA: XBRL DOCUMENT

Note 4 - Commitments and Contingencies (Tables)

6 Months Ended

Dec. 31, 2016

Notes Tables

Schedule of Product Warranty Liability [Table Text Block]

Balance at July 1, 2016	$	566
Warranties issued during the period		59
Settlements made during the period		(67	)
Changes in liability for pre-existing warranties during the period		(5	)
Balance at December 31, 2016	$	553

XML 26 R16.htm IDEA: XBRL DOCUMENT

Note 6 - Derivative Obligations (Tables)

6 Months Ended

Dec. 31, 2016

Notes Tables

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]

	Series A
	December 31, 2016			June 30, 2016
Market price of common stock	$	3.45		$	2.93
Expected volatility		106	%		99	%
Contractual term (years)		4.2			4.7
Discount rate		1.73	%		1.01	%
Dividend rate		0	%		0	%
Exercise price	$	8.00		$	8.00

Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]

	Balance at December 31, 2016		Level 1		Level 2		Level 3

Derivative obligation	$	844	$	-	$	-	$	844

	Balance at June 30, 2016		Level 1		Level 2		Level 3

Derivative obligation	$	670	$	-	$	-	$	670

Derivative Instruments, Gain (Loss) [Table Text Block]

	Amount
Balance – July 1, 2016	$	670
Change in fair value of derivative obligation		174
Balance – December 31, 2016	$	844

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

XML 27 R17.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity (Tables)

6 Months Ended

Dec. 31, 2016

Notes Tables

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life		Aggregate Intrinsic Value

Outstanding at June 30, 2016		104,378		$	14.85

Granted		223,825		$	2.93
Forfeited		(3,835	)	$	16.15
Expired		(2,500	)	$	18.46

Outstanding at December 31, 2016		321,868		$	6.52		6.3	$	129

Vested and Expected to Vest at December 31, 2016		285,743		$	6.88		6.2	$	111

Exercisable at December 31, 2016		157,553		$	9.58		5.9	$	49

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Expected life (years)	4.2
Risk-free interest rate	1.1	%
Expected volatility	102.7	%
Dividend yield	0	%

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]

				Weighted Average
	Number of Shares			Grant Date Fair Value
Balance at June 30, 2016		63,566		$	14.96
Granted		98,417		$	4.97
Vested		(95,902	)	$	10.85
Forfeited		(933	)	$	26.37
Outstanding at December 31, 2016		65,148		$	5.26

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

	Number of Shares		Weighted- Average Exercise Price Per Share
Beginning balance		4,828,721	$	9.37
Warrants granted		--		--
Warrants canceled		--		--
Warrants exercised		--		--

Outstanding at December 31, 2016		4,828,721	$	9.37

Exercisable at December 31, 2016		4,130,192	$	9.60

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 28 R18.htm IDEA: XBRL DOCUMENT

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) $ in Thousands	Mar. 04, 2016 shares	Dec. 31, 2016 USD ($) shares	Jun. 30, 2016 USD ($) shares	Dec. 31, 2015 USD ($)	Jun. 30, 2015 USD ($)
Common Stock, Shares Authorized \| shares	350,000,000	150,000,000	150,000,000
Cash and Cash Equivalents, at Carrying Value		$ 4,899	$ 5,835	$ 2,942	$ 3,357
Working Capital		5,499
Retained Earnings (Accumulated Deficit)		$ (182,106)	$ (156,262)
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20

XML 29 R19.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Details Textual)	6 Months Ended
	Dec. 31, 2016
Maximum Period Of Agreement	21 years
Number of Reportable Segments	1

XML 30 R20.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies - Calculation for Basic and Diluted Earnings Per Share (Details) - shares

6 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Anti-dilutive securities (in shares)

5,215,737

2,548,096

Convertible Debt Securities [Member]

Anti-dilutive securities (in shares)

404,412

Vested Series A Warrants [Member]

Anti-dilutive securities (in shares)

404,410

Unvested Series A Warrants [Member]

Anti-dilutive securities (in shares)

^[1]

698,529

Vested Series B Warrants [Member]

Anti-dilutive securities (in shares)

197,242

Unvested Series B Warrants [Member]

Anti-dilutive securities (in shares)

384,191

Warrant, Other [Member]

Anti-dilutive securities (in shares)

3,725,782

252,620

Employee Stock Option [Member]

Anti-dilutive securities (in shares)

321,868

146,838

Restricted Stock Units (RSUs) [Member]

Anti-dilutive securities (in shares)

65,148

59,854

[1]	The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021.

XML 31 R21.htm IDEA: XBRL DOCUMENT

Note 4 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands		3 Months Ended	6 Months Ended
	Nov. 03, 2016	Dec. 31, 2016	Dec. 31, 2016	Sep. 30, 2015
Short Term Investment Minimum				$ 2,000
Payment Terms, Severance Compensation			1 year
Severance Costs		$ 1,200
Chief Executive Officer [Member]
Termination Costs, Total	$ 1,400
Key Executives [Member]
Potential Severance Costs			$ 506
Minimum [Member]
Period Of Warranty On Products			1 year
Maximum [Member]
Period Of Warranty On Products			2 years

XML 32 R22.htm IDEA: XBRL DOCUMENT

Note 4 - Commitments and Contingencies - Changes In Product Liability Included In Accrued Liabilities (Details) $ in Thousands	6 Months Ended
	Dec. 31, 2016 USD ($)
Beginning balance	$ 566
Warranties issued during the period	59
Settlements made during the period	(67)
Changes in liability for pre-existing warranties during the period	(5)
Ending balance	$ 553

XML 33 R23.htm IDEA: XBRL DOCUMENT

Note 5 - Convertible Debentures (Details Textual) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended	6 Months Ended
	Aug. 22, 2016	Aug. 03, 2016	Feb. 29, 2016	Dec. 31, 2016	Dec. 31, 2015
Stock Issued During Period, Shares, New Issues		600,000
Amortization of Debt Discount (Premium)				$ 10,011	$ 62
Warrants Issued in Connection with Convertible Debentures [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			3,529,412
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 8
Warrant Expiration Period			5 years
Number of Warrants, Percentage of Shares Issued or to Be Issued			80.00%
Boyalife Investment Inc. [Member]
Stock Issued During Period, Shares, New Issues			735,294
Sale of Stock, Price Per Share			$ 3.40
Stock Issued During Period, Value, New Issues			$ 2,500
Convertible Debt [Member] \| Boyalife Investment Inc. [Member]
Debt Instrument, Face Amount			$ 12,500
Debt Conversion, Original Debt Principal, Amount	$ 12,500
Debt Conversion, Original Debt Interest, Amount	8,250
Additional Interest Expense, Debt	3,154
Amortization of Debt Discount (Premium)	9,538
Amortization of Debt Issuance Costs	$ 155
Convertible Debt [Member] \| Boyalife Investment Inc. [Member] \| Common Stock [Member]
Debt Conversion, Convertible Shares			3,676,471
Debt Conversion, Converted Instrument, Shares Issued	6,102,941
Convertible Debt [Member] \| Boyalife Investment Inc. [Member] \| Common Stock [Member] \| Conversion of Interest [Member]
Debt Conversion, Converted Instrument, Shares Issued	2,426,470
Debt Conversion, Converted Instrument, Amount	$ 11,404
Convertible Debt [Member] \| Boyalife Investment Inc. [Member]
Gross Proceeds from Financing Transaction			$ 15,000

XML 34 R24.htm IDEA: XBRL DOCUMENT

Note 6 - Derivative Obligations (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Derivative, Gain (Loss) on Derivative, Net	$ 153	$ 2,180	$ (174)	$ 3,606
Series A Warrant [Member]
Class of Warrant or Right, Outstanding	404,410		404,410

XML 35 R25.htm IDEA: XBRL DOCUMENT

Note 6 - Derivative Obligations - Fair Value Assumptions (Details) - Series A Warrant [Member] - $ / shares	6 Months Ended	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016
Market price of common stock (in dollars per share)	$ 3.45	$ 2.93
Expected volatility	106.00%	99.00%
Contractual term (years) (Year)	4 years 73 days	4 years 255 days
Discount rate	1.73%	1.01%
Dividend rate	0.00%	0.00%
Exercise price (in dollars per share)	$ 8	$ 8

XML 36 R26.htm IDEA: XBRL DOCUMENT

Note 6 - Derivative Obligations - Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016
Derivative obligation	$ 844	$ 670
Fair Value, Inputs, Level 1 [Member]
Derivative obligation
Fair Value, Inputs, Level 2 [Member]
Derivative obligation
Fair Value, Inputs, Level 3 [Member]
Derivative obligation	$ 844	$ 670

XML 37 R27.htm IDEA: XBRL DOCUMENT

Note 6 - Derivative Obligations - Change In Fair Value of Derivative Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Balance			$ 670
Change in fair value of derivative obligation	$ (153)	$ (2,180)	174	$ (3,606)
Balance	$ 844		$ 844

XML 38 R28.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity (Details Textual)					1 Months Ended		3 Months Ended		6 Months Ended
Note 7 - Stockholders' Equity (Details Textual)	Dec. 16, 2016 $ / shares shares	Aug. 03, 2016 USD ($) $ / shares shares	Jul. 26, 2016 shares	Jul. 07, 2016 $ / shares shares	Nov. 30, 2016 USD ($) shares	Jul. 31, 2016 shares	Dec. 31, 2016 USD ($) shares	Dec. 31, 2015 USD ($)	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2015 USD ($) shares
Stock Issued During Period, Shares, New Issues		600,000
Shares Issued, Price Per Share \| $ / shares		$ 4.10
Payments of Stock Issuance Costs \| $		$ 369,000
Proceeds from Issuance of Common Stock \| $		$ 2,091,000							$ 2,091,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period									0	0
Class of Warrant or Right, Exercisable, Intrinsic Value \| $							$ 0		$ 0
Former Chief Executive Officer [Member] \| General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost \| $					$ 539,000
Employee Stock Option [Member]
Allocated Share-based Compensation Expense \| $							735,000		$ 1,033,000	$ 304,000
Allocated Share Based Compensation Reversal \| $								$ (39,000)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									223,825
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares									$ 2.93
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options \| $							$ 259,000		$ 259,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition									2 years
Employee Stock Option [Member] \| Former Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number					72,496
Share-based Compensation Arrangement by Share-based Payment Award, Pre-Modification of Agreement					90 days
Employee Stock Option [Member] \| Interim Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	50,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares	$ 2.91
Number Of Installments	5
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	7 years
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			98,417						98,417
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period							35,902		95,902
Restricted Stock [Member] \| Former Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number					79,720
Short Term Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period						118,288
Shares Paid for Tax Withholding for Share Based Compensation						46,879
The 2016 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				156,100
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares				$ 2.86
The 2016 Plan [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				7 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Ratable Vesting Period				180 days
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				3 years

XML 39 R29.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity - Option Activity for Stock Option Plans (Details) - Employee Stock Option [Member] $ / shares in Units, $ in Thousands	6 Months Ended
	Dec. 31, 2016 USD ($) $ / shares shares
Outstanding, options (in shares) \| shares	104,378
Outstanding, weighted average exercise price, options (in dollars per share) \| $ / shares	$ 14.85
Granted, options (in shares) \| shares	223,825
Granted, weighted average exercise price, options (in dollars per share) \| $ / shares	$ 2.93
Forfeited, options (in shares) \| shares	(3,835)
Forfeited, weighted average exercise price, options (in dollars per share) \| $ / shares	$ 16.15
Expired, options (in shares) \| shares	(2,500)
Expired, weighted average exercise price, options (in dollars per share) \| $ / shares	$ 18.46
Outstanding, options (in shares) \| shares	321,868
Outstanding, weighted average exercise price, options (in dollars per share) \| $ / shares	$ 6.52
Outstanding, weighted average remaining contractual life, options (Year)	6 years 109 days
Outstanding, aggregate intrinsic value, options \| $	$ 129
Vested and Expected to Vest, options (in shares) \| shares	285,743
Vested and Expected to Vest, weighted average exercise price, options (in dollars per share) \| $ / shares	$ 6.88
Vested and Expected to Vest, weighted average remaining contractual life, options (Year)	6 years 73 days
Vested and Expected to Vest, aggregate intrinsic value, options \| $	$ 111
Exercisable, options (in shares) \| shares	157,553
Exercisable, weighted average exercise price, options (in dollars per share) \| $ / shares	$ 9.58
Exercisable, weighted average remaining contractual life, options (Year)	5 years 328 days
Exercisable, aggregate intrinsic value, options \| $	$ 49

XML 40 R30.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity - Schedule of Assumptions (Details)	6 Months Ended
	Dec. 31, 2016
Expected life (years) (Year)	4 years 73 days
Risk-free interest rate	1.10%
Expected volatility	102.70%
Dividend yield	0.00%

XML 41 R31.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity - Restricted Stock Activity Granted to Employees (Details) - Restricted Stock [Member] - $ / shares		3 Months Ended	6 Months Ended
	Jul. 26, 2016	Dec. 31, 2016	Dec. 31, 2016
Balance, Number of Shares, (in shares)			63,566
Balance, Weighted Average Grant Date Fair Value, (in dollars per share)			$ 14.96
Granted, Number of Shares (in shares)	98,417		98,417
Granted, Weighted Average Grant Date Fair Value (in dollars per share)			$ 4.97
Vested, Number of Shares (in shares)		(35,902)	(95,902)
Vested, Weighted Average Grant Date Fair Value (in dollars per share)			$ 10.85
Forfeited, Number of Shares (in shares)			(933)
Forfeited, Weighted Average Grant Date Fair Value (in dollars per share)			$ 26.37
Outstanding, Number of Shares, (in shares)		65,148	65,148
Outstanding, Weighted Average Grant Date Fair Value, (in dollars per share)		$ 5.26	$ 5.26

XML 42 R32.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity - Warrant Activity (Details) - Restricted Stock [Member]	6 Months Ended
	Dec. 31, 2016 $ / shares shares
Beginning balance (in shares) \| shares	4,828,721
Beginning balance (in dollars per share) \| $ / shares	$ 9.37
Warrants granted (in shares) \| shares
Warrants granted (in dollars per share) \| $ / shares
Warrants canceled (in shares) \| shares
Warrants canceled (in dollars per share) \| $ / shares
Warrants exercised (in shares) \| shares
Warrants exercised (in dollars per share) \| $ / shares
Outstanding at December 31, 2016 (in shares) \| shares	4,828,721
Outstanding at December 31, 2016 (in dollars per share) \| $ / shares	$ 9.37
Exercisable at December 31, 2016 (in shares) \| shares	4,130,192
Exercisable at December 31, 2016 (in dollars per share) \| $ / shares	$ 9.60

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�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end

Note 7 - Stockholders' Equity - Warrant Activity (Details) - Restricted Stock [Member]	6 Months Ended
	Dec. 31, 2016 $ / shares shares
Beginning balance (in shares) \| shares	4,828,721
Beginning balance (in dollars per share) \| $ / shares	$ 9.37
Warrants granted (in shares) \| shares
Warrants granted (in dollars per share) \| $ / shares
Warrants canceled (in shares) \| shares
Warrants canceled (in dollars per share) \| $ / shares
Warrants exercised (in shares) \| shares
Warrants exercised (in dollars per share) \| $ / shares
Outstanding at December 31, 2016 (in shares) \| shares	4,828,721
Outstanding at December 31, 2016 (in dollars per share) \| $ / shares	$ 9.37
Exercisable at December 31, 2016 (in shares) \| shares	4,130,192
Exercisable at December 31, 2016 (in dollars per share) \| $ / shares	$ 9.60